

PROPHYLAXIS OF THROMBOSIS WITH LOW-MOLECULAR-WEIGHT HEPARIN (LMWH)

R. G. Holzheimer

University of Halle-Wittenberg, Germany

Abstract: Deep vein thrombosis (DVT) and pulmonary embolism (PE) are a major cause of morbidity and mortality, affecting approximately 4 million people each year in the United States.

The identification of risk factors for the development of DVT and PE helped to develop a system for risk stratification. The risk to develop a deep vein thrombosis has been estimated to be up to 80% in some populations without prophylaxis. In multiple studies LMWHs demonstrated to be efficient and safe for reduction of DVT of patients in general and visceral surgery, orthopedic surgery, and trauma. Three compounds have been studied best, e.g., dalteparin, enoxaparin, nadroparin, which may help to decide which type of LMWH to use. There is clearly an expanding role for LMWHs in gynecology, cancer, intensive care, patients with acute medical illness and bedridden patients.

In summary, LMWHs have chemical, physical, and clinical similarities. They have greater bioavailability, longer half-lives, more predictable pharmacological response, possible improved safety, and similar or greater efficacy compared with UH. However, the evaluation of clinical trials does not allow the determination of therapeutic equivalence due to different diagnostic methods, drug administration times, dose equivalencies, and outcome measurements. The scoring of the quality of clinical trials for meta-analysis is problematic and it has been recommended to assess the methodological aspects individually.

Despite clear evidence of effectiveness, deep vein thrombosis prophylaxis is underused. This has been recognized by law firms as evidenced by internet advertisement where patients are informed on the prevention of venous thromboembolism or economy class syndrome. "If you or a family member has been injured, contact a personal injury attorney today. Just fill out Injury.Board.com's on-line questionnaire and have a personal injury lawyer review your potential personal injury claim - free of charge.". The medico legal implications of antithrombotic prophylaxis and treatment are well recognized.

Key words: LMWH; dalteparin; enoxaparin; nadroparin; deep vein thrombosis; pulmonary embolism; prophylaxis

INTRODUCTION

In 1980, unfractionated heparin (UFH) was the established agent for the prophylaxis of venous thromboembolic (VTE) disease in patients undergoing general surgery (Breddin 2000). The commercial use of low molecular weight heparins (LMWHs) began in the mid 1980s for hemodialysis and the prophylaxis of deep vein thrombosis (DVT). In the initial stages of development of these drugs only dalteparin, enoxaparin, and nadroparin were used. (Mousa 2002). Low-molecular-weight heparins (LMWH), mixtures of heparin molecules in the range of 3,000 to 10,000 daltons represent a major clinical advance in anticoagulation since the identification of unfractionated heparin (UFH) in 1922 and the introduction of the synthetic coumarin derivative, warfarin, in 1948. Their predictable pharmacokinetics, increased bioavailability, and longer plasma half-life allow for once- or twice-daily dosing and eliminate the need for routine laboratory monitoring (Huang and Shimamura 1998). At equipotent antithrombotic doses, LMWHs produce less bleeding than does unfractionated heparin. The pharmacokinetic characteristics of LMWHs permit their use in a fixed dose administered subcutaneously without monitoring, resulting in greater clinical utility than standard heparin (Turpie 1997). Each LMWH is viewed as a unique drug by regulatory agencies because of their differing physical and pharmacokinetic attributes (Kleinschmidt and Charles 2001). Their anti-Xa/anti-IIa ratio varies significantly, and the injection of the same dose generates different anti-Xa activities and activated partial thromboplastin time (APTT) prolongations (Boneu 2000). The type of prophylaxis varies largely: (1) standard low-dose heparin (5000 U administered subcutaneously 2-3 times per day); (2) adjusted-dose heparin (adequate to elevate the activated partial thromboplastin time to 5 seconds above the upper limit of normal); and (3) low-molecular-weight heparin (30 mg subcutaneously twice daily without monitoring) (Owings and Blaisdell 1996). Not every patient with major intra-abdominal surgery or orthopedic surgery has obtained prophylaxis against deep vein thrombosis: 84.3% hip replacement, 75.9% knee replacement, 45.2% hip fracture repair and 50.3% abdominal surgery pa-

tients received prophylaxis (Stratton et al. 2000), although the impact on the clinical acceptance of LMWH and the cost savings of prophylaxis are well understood (Geerts et al. 2001; Bick and Haas 2003).

PROPHYLAXIS IN GENERAL AND VISCERAL SURGERY

INCIDENCE

Venous thromboembolism (VTE) continues to be an important cause of death in hospitalized patients undergoing major elective surgery. Approximately 500,000 cases of deep vein thrombosis (DVT) and pulmonary embolism (PE) occur in the United States each year. Of those patients who suffer a massive PE, 70% die within the first hour of symptom onset. (Muntz 2000). A study of autopsy-proven pulmonary embolism in hospital patients showed that VTE accounted for 10% of deaths. Recognition of non-fatal thromboembolism continues to be a problem (Kakkar and de Lorenzo 1998; Lausen et al. 1995). Epidemiology, etiology and diagnosis of venous thromboembolism have been reviewed in another paper of this issue (Gathof et al. 2004).

RISK FACTORS

Several risk factors for thromboembolic events have been characterized in general surgery patients: previous thromboembolism, obesity, varicose veins, malignancy, preoperative hospitalization, estrogen therapy, chronic cardiac disease, bronchitis, leg fracture or arthroplasty, present leg ulcer, operating times longer than 150 minutes, preoperative transfusion (Samama et al. 1988; Flordal et al. 1996; Miller et al. 2002). Three levels of risk to develop DVT were identified: low level (less than 10%), moderate (10-40%) and high (40-80%) (Bergqvist et al. 1992). Together with acquired risks conditions of thrombophilia, caused by deficiencies in coagulation inhibitors (antithrombin III, protein C, protein S) or alteration of the anticoagulation system as resistance to activated protein C or antiphospholipid antibodies may increase the risk for DVT (Storti et al. 1996). The aging process is associated with increased coagulation and fibrinolysis parameters, which may multiply the risk of thromboembolism in this population (van Gorp et al. 1998). Certain types of operations, e.g., hip or knee arthroplasty, are at highest risk for DVT or PE (Muntz 2000). Risk stratification and thromboprophylaxis modalities are reviewed by Bick and Kaplan (2004).

COMBINATION PROPHYLAXIS

Prophylaxis of venous thromboembolism is aimed at the prevention of thrombosis by pharmacological methods, e.g., unfractionated heparin (UH), low-molecular weight heparin (LMWH), oral anti-coagulants, and physical methods, e.g., elastic grad-

uated compression stockings (GCS) and systems of intermittent pneumatic calf compression. GCS are effective in diminishing the risk of DVT in hospitalized patients. The combination of physical and pharmacological methods seems to be the optimal prophylaxis (Wille-Jorgensen et al. 2003; Amarigiri and Lees 2000; Storti et al. 1996). The addition of other pharmacological compounds may be more effective than LMWH alone for preventing symptomatic thromboembolism (Tsimoyiannis et al. 1996); yet there is a need for cost-effective analysis. The significance of available methods for prophylaxis of DVT and PE has been reported in the recommendations of the sixth ACCP Consensus Conference on Antithrombotic Therapy (Geerts et al. 2001) and in another chapter of this issue (Bick and Kaplan 2004).

EFFICACY AND SAFETY OF LMWH

With regard to reduction of venous thrombotic events efficacy has been demonstrated for LMWHs (dalteparin, enoxaparin, fraxiparin) in comparison to UH (The European Fraxiparin Study Group 1988; Bergqvist et al. 1990; Bergqvist et al. 1992; Ockelford et al. 1989; Nurmohamed et al. 1995). However, further clinical studies and meta-analyses did not unanimously report that LMWH are more efficient than UH in general surgery patients (Leizorovicz et al. 1993; Jorgensen et al. 1993; Bounameaux et al. 1993; Nurmohamed et al. 1992; Palmer et al. 1997; Koch et al. 1997). Simplified handling of the prophylaxis with LMWH when compared to UH is acknowledged, in general, but the assessment of safety has varied considerably (Kakkar 1993). Some authors reported a higher risk of bleeding complications with LMWH (Koch et al. 1997; Koch et al. 2001; Ho et al. 1999; Clagett and Reisch 1988; Bergqvist et al. 1988). It has been demonstrated that LMWHs may be associated with a higher risk for bleeding when administered in higher doses (Samama et al. 1988; Flordal et al. 1996), whereas low-dose LMWH may have less bleeding episodes (Kakkar et al. 1997; Kakkar et al. 1993; Hartl et al. 1990; Mismetti et al. 2001; Kakkar et al. 1998). Although a correlation between plasma anti-Xa activity and body weight has been observed for some LMWH, the question for the right dosage has not been answered for all LMWHs and circumstances - LMWH at doses below 3400 anti-Xa units seemed to be effective as and safer than UH (Leizorovicz et al. 1993; Mismetti et al. 2001). On balance, LMWH and low-dose unfractionated heparin appear to be equally efficacious in preventing DVT in general surgery patients with the advantage of a once daily administration of LMWH (Geerts et al. 2001).

TIMING OF PROPHYLAXIS

Timing of prophylaxis is also an important issue. Late thromboembolic complications after cessation of postoperative prophylaxis are known to occur up to 7 weeks after surgery. The incidence may be

1%, but could be 10 times higher when special screening was performed (Wille-Jorgensen et al. 1993). Prevention of thromboembolism is not strictly limited to a 2-hour interval between start of prophylaxis and onset of surgery but may also be provided by starting prophylaxis with LMWH during the evening before surgery and continuing post-operatively (Haas and Flosbach 1993; Bergqvist et al. 1995). In Europe, prophylaxis is started pre-operatively and the usual duration for the post-operative period may be 7 days or until the patient is discharged from the hospital (Kakkar and De Lorenzo 1998). Patients with emergency abdominal surgery may benefit even when the prophylaxis is started 24 hours later (Bergqvist et al. 1996). The prolonged administration of LMWH seems not to be justified in general surgery (Sarasin and Bounameaux 1996; Lausen et al. 1998; Kakkar et al. 1993).

COSTS OF LMWH PROPHYLAXIS

Although heparin and LMWH may be equally effective, low-dose heparin has been considered a more economically attractive choice for thromboembolism prophylaxis after colorectal surgery in North-America (Etchells et al. 1999; McLeod et al. 2001); this, however, is largely depending on the price of the LMWH and the costs for handling thromboprophylaxis in the hospital which may be different from country to country (Bergqvist et al. 1996).

MANAGEMENT OF PATIENTS WITH CHRONIC ANTICOAGULANT THERAPY OR SPECIAL DISEASE

The management of patients who require temporary interruption of oral anticoagulant therapy because of surgery or other invasive procedures has to balance the patient's risk of thromboembolic event when anticoagulant therapy is interrupted and the risk of bleeding that is associated with the surgery or procedure (Douketis 2002). Dental procedures, cataract surgery and diagnostic endoscopy may be performed without discontinuing anticoagulation. Perioperative thromboprophylaxis or bridging may be necessary for patients with prosthetic heart valves, atrial fibrillation, hypercoagulable states and chronic venous thrombosis. Consensus on the appropriate perioperative treatment of patients on long-term warfarin therapy is lacking. Low molecular weight heparins (LMWHs) may have an advantage over unfractionated heparin (UH) that perioperative conversion from warfarin with LMWH can be carried out in an outpatient setting (Spandorfer et al. 1999; Jafri 2004). Although LMWH offers many advantages over UH, in patients with renal dysfunction, obesity and pregnancy its use is less clearly defined and may involve further risks (Nagge et al. 2002; Howard 2003).

PROPHYLAXIS IN LAPAROSCOPIC SURGERY

Indication for thromboprophylaxis may vary widely and not all surgeons do accept prophylaxis with

LMWH as an option. Only 20% of the surgeons asked considered that thromboembolism, despite the risk of thromboembolic disease due to use of the laparoscopic pneumoperitoneum, was a problem (Bradbury et al. 1997; Lord et al. 1998; Filtenborg Tvedskov et al. 2001).

PROPHYLAXIS IN UROLOGY

There is a lack of well-designed clinical studies that meet the methodological criteria as published by the American College of Chest Physician. Patients at normal risk may benefit from LMWH prophylaxis. In high-risk patients a combination with mechanical prophylaxis has been suggested (Geerts et al. 2001; Bick and Kaplan 2004).

PROPHYLAXIS IN VASCULAR SURGERY

CAROTID ARTERY DISSECTION

Extracranial internal carotid artery dissection can lead to occlusion of the artery and hence can cause an ischemic stroke. Antithrombotic agents (heparin, oral anticoagulants or antiplatelet drugs) may prevent arterial thrombosis. A Cochrane analysis of 26 studies including 327 patients found no evidence to support their routine use (Lyrer and Engelter 2003).

INFRAINGUINAL BYPASS, ARTERIAL RECONSTRUCTIVE SURGERY AND ANGIOPLASTY

Chronic peripheral arterial disease (PAD) is frequently treated by implantation of either an infrainguinal autologous venous or artificial graft. To prevent graft occlusion - one-year occlusion rates vary between 15% and 75% - patients receive either an antiplatelet or antithrombotic drug, or a combination of both (Dorffler-Melly et al. 2003). There are only few studies investigating LMWH in the prophylaxis in arterial thrombosis. LMWH may be used successfully for maintenance of graft patency (Edmondson et al. 1994; Samama and Gigou 1995). Again, the use of high dose LMWH may be associated with increased bleeding rates (Kujath et al. 2002). The evidence is not conclusive which may be the best form to prevent occlusion (vitamin K antagonist, aspirin, LMWH) (Dorffler-Melly et al. 2003) and unfortunately many trials have significant deficiencies (Watson et al. 1999). In preliminary investigations extensive dissections after percutaneous transluminal angioplasty (PTA) might benefit from extended prophylaxis with LMWH (Schweizer et al. 2001). Postoperative deep vein thrombosis after aortic surgery may be prevented by LMWH, best by direct injection into the aorta (Farkas et al. 1993; Wilson et al. 1991).

STENT, PERCUTANEOUS CORONARY INTERVENTION (PCI), CORONARY ANGIOPLASTY

Stents were successfully used for coronary revascularization in recent years, but have also been associ-

ated with a high rate of stent thrombosis. LMWH administered by subcutaneous injection may provide an effective alternative to the use of intravenous heparin after stent implantation (Stables and Sigwart 1996; Zidar 1997). LMWH may produce significantly fewer clinical events and vascular complications than the conventional warfarin anticoagulation (Zidar 1998; Pan et al. 1996; Kereiakes et al. 2001; Furman et al. 2001; Choussat et al. 2002; Bhatt et al. 2003; Moliterno et al. 2003; Batchelor et al. 2001). Intramural delivery may not improve the outcome after stent deployment (Meneveau et al. 2000) nor may do the prolonged administration of LMWH (Grassman et al. 2001). Stents used for transjugular intrahepatic portosystemic shunt (TIPS) may be thrombogenic and have a high risk of early shunt insufficiency, which may be prevented by periprocedural heparin (Siegerstetter et al. 1997).

CORONARY ARTERY BYPASS

The effect of preoperative administration of LMWH in patients undergoing coronary artery bypass has been studied with conflicting results with regard to hemoglobin values, postoperative bleeding or blood product transfusion when compared to UH (Kincaid et al. 2003; Medalion et al. 2003).

PROSTHETIC VALVE IMPLANTATION

In contrast, in patients with mechanical heart valve implantation, LMWH may compare favorably with UH or acenocumarol (Montalescot et al. 2000; Ferreira et al. 2003) leading to a shorter length of stay and decreased postoperative costs (Fanikos et al. 2004).

PROPHYLAXIS IN TRAUMA PATIENTS

Deep vein thrombosis and pulmonary embolism are major risks in patients experiencing major trauma. The reported incidence of deep venous thrombosis ranges from 20 to 90%. The reported incidence of pulmonary embolism varies between 2.3 and 22%. There may be an increased risk of thromboembolism due to the aging population and survival of more severely injured patients (Hak 2001). Color-flow duplex proved to be a sensitive method for detecting thrombi. Unfortunately there was no correlation of the risk assessment profile for thromboembolism (RAPT) scale with the occurrence of DVT (Greenfield et al. 1997).

SPINAL CORD INJURY

The incidence of DVT without prophylaxis in acute spinal cord injury patients varies from 49% to 100% in the first 12 weeks with the first 2 weeks having the highest rate following acute injury (Atia et al. 2001; Merli et al. 1993). Single agent pharmacological therapy with adjusted dose heparin is effective but carries some risk of bleeding. Combination prophylaxis may consist of external pneu-

matic compression sleeves, aspirin, dipyridamole, and low-dose heparin for 8 to 12 weeks (Merli et al. 1993). Several studies have demonstrated that LMWH compares favorably or may be even superior to UH (Green et al. 1990; Green et al. 1994; Harris et al. 1996; Chiou-Tan et al. 2003; Spinal Cord Injury Thromboprophylaxis Investigators 2003). In more recent studies a 3-month duration of prophylaxis has been recommended, in case of non-responders with vena cava filter (Anonymous 2002).

BRAIN INJURY

Anticoagulant prophylaxis for patients with head injury who suffered intracranial bleeding or who need intracranial surgery has been debated. A diversity of practice and opinion together with a concern about the failure to implement even the simplest means of prophylaxis has been recently reported (Cupitt 2001).

BLUNT TRAUMA

In contrast, LMWH were successfully applied in patients with closed head injuries and nonoperatively treated solid abdominal organ injuries (Norwood et al. 2001). LMWHs were equally safe or even more effective than low-dose heparin in preventing venous thromboembolism after major trauma (Geerts et al. 1996; Knudson et al. 1996; Haetjens 1996).

HIP FRACTURE

Dosage and optimal initiation of thromboembolic prophylaxis continue to be a matter of dispute (Monreal et al. 1989). LMWH may be as effective and safe compared to UH (Thaler et al. 2001; Kew et al. 1999; Jorgensen et al. 1992). In older patients a reduction of dose has been recommended (Barsotti et al. 1990). Efficacy or safety of LMWH in patients undergoing hip fracture surgery was not different (The TIFDED Study Group 1999), but new synthetic LMWH may have an advantage (Eriksson et al. 2001).

LEG INJURY

Deep vein thrombosis is common in persons with leg injury requiring prolonged immobilization. The incidence may vary from 4.3% to 29%; LMWH prophylaxis demonstrated a significant reduction of thromboembolic events in most studies but one (Kock et al. 1995; Kujath et al. 1993; Spannagel and Kujath 1993; Lassen et al. 2002; Jorgensen et al. 2002).

COMBINED PROPHYLAXIS

Intermittent pneumatic compression (IPC) devices or sequential treatment by Flowtron DVT garments have been reported to improve the outcome of thromboprophylaxis in trauma patients (Ginzburg et al. 2003; Eskander et al. 1997).

LONG-TERM PROPHYLAXIS

In patients with contraindications to coumarin prophylaxis LMWH may be successfully applied for long-term prophylaxis, especially when there is recent blood loss, gastroduodenal ulcer disease, psychological or physical inability or unwillingness for monitoring, chronic alcoholism, dementia, pregnancy, recent neurosurgery, pericardial effusion or age above 80 years (Monreal et al. 1994).

COST-EFFECTIVENESS

Cost-analysis studies on the use of LMWH prophylaxis in trauma patients came out with different conclusions. Prophylaxis may save costs provided the price for the compound is right (Wade et al. 2000) or concluded that no method was superior to any other or to no prophylaxis (Velmahos et al. 2000). Neither concerns about the higher cost of LMWH nor the financial implications of major bleeding should preclude the use of LMWH in trauma patients (Shorr and Ramage 2001). With rising health care cost, thromboprophylaxis with LMWH should be able to decrease the length of hospital stay without compromising care. The 1998 American College of Chest Physicians guidelines recommend thromboprophylaxis with LMWH and oral warfarin in trauma patients. The LMWH Expedited Anticoagulation Program (LEAP) has successfully decreased hospital days (Bridges et al. 2003).

PROPHYLAXIS IN INTENSIVE CARE AND ACUTELY ILL MEDICAL PATIENTS

10% - 30% of medical and surgical intensive care patients develop DVT within the first week of intensive care treatment. Approximately 60% of trauma intensive care patients developed DVT within the first 2 weeks of admission. The estimated prevalence of DVT in neurosurgical intensive care patients not given prophylaxis ranges from 22% to 35%. Intensive care patients with spinal cord injury may develop DVT in 50% to 80% of cases (Attia et al. 2001). Both undetected and clinically evident DVT can seriously impact the prognosis in critically ill patients or prolong the recovery from the original illness. LMWH may be more effective than UH in critically trauma patients, high dose LMWH in seriously ill medical patients. LMWH appears to be superior to UH in acute stroke patients (Davidson 2000). All patients should be assessed for their risk of thromboembolism and then prophylaxis should be started individually with regard to initiation, monitoring, and dosage adjustment. When bleeding is expected, mechanical prophylaxis may be applied until the bleeding risk decreases; all others should receive UH or LMWH (Geerts et al. 2001).

HEMOFILTRATION

Filter survival time in hemofiltration, e.g., high-volume continuous venovenous hemofiltration, may

depend on baseline platelet count. LMWH provide identical filter life, comparable safety but increased costs compared to UH. Patients with higher platelet count may benefit from adjusted dosage of LMWH (Reeves et al. 1999; de Pont et al. 2000). LMWHs have been successfully applied in hemodialysis and hemofiltration, but there is an urgent need for more clinical evaluation (Sagedal and Hartmann 2004).

ACUTELY ILL MEDICAL PATIENTS

Medical patients represent the majority of hospitalized patients, and at least 75% of fatal pulmonary emboli occur in this group. Medical patients are at significant risk of DVT, yet the clinical benefit and cost-effectiveness of routine thromboprophylaxis in medical patients have been discussed controversially (Cohen 2002). In recent trials LMWH (dalteparin, enoxaparin, nadroparin) have been successfully tested in medical patients with heart failure, respiratory failure, infectious disease, rheumatic disorder, unstable angina, acute myocardial infarction and atrial fibrillation (Harenberg et al. 1990; Harenberg et al. 1993; Glick et al. 1996; Bijsterveld et al. 2002; Lamy et al. 2002; de Lissovoy and Subedi 2002; Kleber et al. 2003; Gardlund 1996; Samama et al. 1999; Fraisse et al. 2000; Turpie 2000; Lechler et al. 1996). Anticoagulation, UH and LMWH are used in patients with myocardial infarction. The effect of LMWH or UH on the development of VTE after myocardial infarction is not known (Geerts et al. 2001). Critically ill patients with normal renal function may have significantly lower anti-Xa levels in response to a single daily dose of subcutaneous LMWH when compared with medical patients in the normal ward (Priglinger et al. 2003). Rebound coagulation activation may occur shortly after discontinuation of UH and LMWH. A longer duration or weaning of treatment, or continuation with other anticoagulant treatment may reduce this effect (Bijsterveld et al. 2002). Economic analysis indicated that prophylaxis with LMWH may induce a small increase in current treatment cost but may avoid long-term costs, e.g., avoidance of incremental cost per VTE and/or future VTE treatment (de Lissovoy and Subedi 2002). Further improvement of prophylaxis will be available when the impact of LMWH on clinically important endpoints, e.g., objectively confirmed DVT, fatal or non-fatal PE, proximal DVT, sudden death, has been investigated (Vaitkus et al. 2002). Low-dose unfractionated heparin or LMWH significantly decrease the incidence of thromboembolic events when compared with no prophylaxis in medical patients, while LMWH is followed by less bleeding events (Geerts et al. 2001). Vaitkus has reviewed the results of recent trials in thromboprophylaxis in immobilized medical patients (2004).

NEPHROTIC SYNDROME AND CHRONIC RENAL FAILURE

The nephrotic syndrome carries a high risk of thrombotic complications, which has lead to an-

tithrombotic prophylaxis in patients at risk (albuminemia < 20g/l and membranous nephropathy) either by LMWH or antivitamin K (Rostoker et al. 1995). LMWH may suppress macroscopic clot formation and fibrinolytic activity (Ryan et al. 1991). Concomitant coumarin use may enhance the effect (Janssen et al. 1996). A recombinant tissue plasminogen activator has been successfully tested as alternative treatment (Schenk et al. 2000).

GERIATRIC PATIENTS

Bedridden elderly patients with an acute medical illness are at increased risk to develop DVT. Just recently studies have shown that LMWH may successfully reduce the risk to develop DVT (Bergmann and Neuhart 1996; Harenberg et al. 1996).

PROPHYLAXIS IN PATIENTS WITH MALIGNANT TUMORS

CANCER PATIENTS UNDERGOING SURGERY

Patients undergoing major abdominal or pelvic surgery for malignancy are at particularly high risk of developing VTE. About 40% of VTE occur after discharge from the hospital (Khusal et al. 2002). Certain malignant tumors are prone to support the development of DVT, e.g., breast and pelvic cancer, ovarian cancer, head and neck cancer (Maxwell et al. 2001; von Tempelhoff et al. 2000; von Tempelhoff et al. 1997; Gondret et al. 1995). Several studies in patients in cancer patients undergoing surgery demonstrated that the use of LMWH is as effective as UH but with a major advantage in handling (once daily versus three times daily application) (Fricker et al. 1988; Enoxacan Study Group 1997; Boncinelli et al. 2001). Hemorrhage was not seen to be an adverse event in these patients (Bergqvist et al. 1990; Baykal et al. 2001), these patients may even benefit from a higher dosage of LMWH which may be weight adjusted (Wiig et al. 1995; Baykal et al. 2001). Prolonged prophylaxis may help to avoid the occurrence of post discharge VTE (Bergqvist 1996; Khusal et al. 2002; Rasmussen 2002) and may even have an effect on cancer survival (von Tempelhoff et al. 2000). Postoperative prophylaxis may be improved by simultaneous application of LMWH and external pneumatic compression (Maxwell et al. 2001).

PROPHYLAXIS IN CANCER PATIENTS

Patients with cancer who present with both a greater thrombus burden and more pronounced derangement of the coagulation system are at increased risk to develop DVT, venous thromboembolism (VTE) and PE. Central venal catheters used for the administration of chemotherapy have been associated with a number of complications, thrombosis and infection. LMWH reduced the rate of upper extremity thrombosis to 6% in comparison to 62% without prophylaxis (Monreal et al. 1996). Whereas some investigators reported a similar benefit-to-risk ratio for warfarin and LMWH (Mismetti

et al. 2003), the use of UH may not reach this level of protection (Klerk et al. 2003). In general LMWH may be superior to oral anticoagulants with regard to a reduction of the risk to develop VTE or bleeding rates (Lee et al. 2003; Meyer et al. 2002). The administration may not prevent the disseminated intravascular coagulation syndrome (DIC) (Chojnowski et al. 2002) but may help to prevent the recurrent VTE, which is more likely to occur in patients with cancer, chronic cardiovascular disease and chronic respiratory disease (Douketis et al. 2000). It has been successfully demonstrated that the prolonged administration of LMWH reduces the incidence of venographically demonstrated thrombosis (Bergqvist et al. 2002) and is at least as effective but safer than oral anticoagulation (Meyer et al. 2002; Levine 2003). Lastly, the potential antineoplastic effects of LMWHs make these more attractive options in cancer patients (Bergqvist 2002; Kakkar 2003; Lee 2003). Pathogenesis, epidemiology of venous thromboembolism and the available prophylaxis/treatment modalities were reviewed by Petralia and Kakkar (2004).

PROPHYLAXIS IN GYNECOLOGY

INCIDENCE AND RISK

VTE are a major cause of maternal mortality and morbidity. The reported overall risk of deep venous thrombosis in gynecological surgery ranges from 7-45%. Fatal pulmonary embolism may occur in nearly 1% of these women (Gates et al. 2002; Oates-Whitehead et al. 2003). The risk for VTE is higher in pregnant than in non-pregnant patients (Laurent et al. 2002). Risk factors for VTE may be cesarean section, a personal or family history of VTE, and inherited or acquired thrombophilias (Gates et al. 2002; Heilmann et al. 2000; Greer 2003). VTE may lead to adverse events such as intrauterine growth restriction, stillbirth, severe early onset preeclampsia and placental abruption (Walker et al. 2003). Anticoagulative prophylaxis seems to be reasonable for women at risk (Friederich et al. 1996). A comprehensive review of the prevention of venous thromboembolism in pregnancy has been presented by Greer (2004).

INDICATION

LMWH has been recommended for prophylaxis of deep vein thrombosis in pregnancy, for prevention of fetal loss, and for decreasing the risk of premature delivery in pregnant women with antiphospholipid syndrome (Makatsaria et al. 2003) and when cesarean section is planned (Burrows et al. 2001). LMWH may be an alternative for patients with a contraindication to coumarin therapy (Monreal et al. 1994).

PREGNANCY, LATE PREGNANCY

Several LMWHs (dalteparin, enoxaparin, nadroparin) have been successfully tested in pregnancy

(Nelson-Piercy et al. 1997; Gibson et al. 1998; Pettila et al. 1999; Blomback et al. 1998; Makatsaria et al. 2003).

PHARMACOKINETICS DURING PREGNANCY

Increased renal clearance during pregnancy may influence the pharmacokinetics of LMWH (Casele et al. 1999; Jacobsen et al. 2003).

BLEEDING AND DOSE

The incidence of bleeding complications is often related to the dose of LMWH; at a lower dose this may be avoided (Ellison et al. 2000; Borstad et al. 1992; Borstad et al. 1988). LMWH and simultaneous administration of epidural analgesia should be used with caution (American College of Obstetricians and Gynecologists 2002).

PROSTHETIC HEART VALVES

The efficacy of LMWH at preventing valve thrombosis remains uncertain (Rowan et al. 2001), although this may not be the case for all LMWHs (Makatsaria et al. 2003). The use of LMWHs is not recommended for pregnant women with prosthetic heart valves (American College of Obstetricians and Gynecologists 2002).

OSTEOPOROSIS

Long-term prophylaxis with UH may bear a risk for osteoporosis; this may be avoided by the use of LMWH (Pettila et al. 2002).

PREGNANCY LOSS

Patients with recurrent pregnancy loss associated with factor V Leiden mutation may benefit from LMWH prophylaxis (Younis et al. 2000).

CONTROVERSY

INHERITED THROMBOPHILIA

While the majority of women with thrombophilia will have an uneventful gestation, it has been demonstrated that thrombophilia is more prevalent in women with pregnancy loss, early onset pre-eclampsia, placental abruption, and severe intrauterine growth retardation (Brenner and Kupferminc 2003). There is a dire lack of randomized trials on the efficacy of heparin or other coagulation modulators on pregnancy in patients with inherited thrombophilias (Gebhardt and Hall 2003; Walker et al. 2003).

ANTIPHOSPHOLIPID SYNDROME

There is a consensus on thromboprophylaxis for antiphospholipid syndrome: LMWH and low dose aspirin are recommended (Gebhardt and Hall 2003; Tincani et al. 2003; Triolo et al. 2003).

WARFARIN, UNFRACTIONATED HEPARIN, LMWH, ASPIRIN

Thromboprophylaxis should be offered, but there is insufficient evidence on which to base recommendations for thromboprophylaxis during pregnancy and the early postnatal period (Gates et al. 2002; Hague et al. 2001). Evidence suggests that UH and LMWH are equally effective in preventing DVT and warfarin may be equally effective as UH. There is no evidence to suggest that warfarin, heparin or aspirin reduce the incidence of PE (Oates-Whitehead et al. 2003). In prophylaxis settings, dalteparin and enoxaparin have been most widely studied and priority should be given to those products (Laurent et al. 2002; Greer 2002).

PROSTHETIC HEART VALVES

The ideal anticoagulation regimen in pregnant patients with prosthetic heart valves is uncertain. Oral dicoumarol anticoagulants, LMWH, subcutaneous high dose heparin and continuous high-dose intravenous heparin have their advantages and disadvantages (Mahesh et al. 2002). Oral anticoagulants may cross the placental barrier and have been accused to cause embryopathy and other adverse effects to the fetus (Bates 2002). Evidence for LMWH prophylaxis is scarce and there may be a high rate of treatment failure (Leyh et al. 2003). The report on treatment failures and concerns about teratogenicity with use of LMWH has been heavily criticized by experts (Ginsberg et al. 2003).

ANTI-Xa ACTIVITY AND ANTITHROMBOTIC PROPERTIES OF LMWHs IN PREGNANCY

LMWHs may differ in their effects on haemostatic parameters, but this may not necessarily lead to clinical differences of these agents (Ellison et al. 2001). During pregnancy, differences in the pharmacokinetics of LMWH were observed, with an overall reduction in anti-Xa activity (Sephton et al. 2003).

PROPHYLAXIS IN NEUROLOGY AND NEUROSURGERY

NEUROSURGERY PATIENTS

VTE is a frequent complication following craniotomy for brain tumors. Several studies in elective neurosurgery patients with LMWH prophylaxis were successfully performed without major bleeding events which may be attributable to the LMWH (Iorio and Agnelli 2000; Walsh and Kakkar 2001); one study was terminated because of the increased incidence of adverse events, e.g., intracranial hemorrhage (Dickinson et al. 1998). The combination with intermittent pneumatic compression (IPC) may attribute to the reduction of VTE (Goldhaber et al. 2002; Macdonald et al. 2003; Agnelli et al. 1998; Nurmohammed et al. 1996). In traumatic intracranial hemorrhagic injuries or intracranial

aneurysm ruptures a routine LMWH should be avoided during the early postoperative period (Siironen et al. 2003; Norwood et al. 2002). Preliminary studies showed that preoperative blood tests for haemostatic markers, e.g., soluble fibrin polymers (SFP) or D-dimer, might help to identify patients at risk (Sonaglia et al. 1999; Vukovich et al. 1997). Patients undergoing operations at the vertebral disc may benefit from antithrombotic prophylaxis with LMWH (Voth et al. 1992).

STROKE

The results of studies with LMWH prophylaxis in acute stroke are controversial. LMWH may be superior to aspirin in preventing DVT but may result in a higher rate of symptomatic intracranial hemorrhage (Sandset et al. 1990; Berge et al. 2000; Bath et al. 2001). In other studies LMWH has been successful in preventing DVT without the induction of bleeding (Prins et al. 1989; Hillbom et al. 2002). Low-dose unfractionated heparin, LMWH have been recommended for patients with acute stroke. In case of hemorrhagic stroke, the situation is less clear and mechanical prophylaxis may be better than LMWH (Geerts et al. 2001). Thromboprophylaxis and antithrombotic therapy in patients with ischemic stroke and cerebral venous/sinus thrombosis have been reviewed by Busch and Masuhr (2004).

PROPHYLAXIS IN PEDIATRIC PATIENTS

Although thrombosis is less frequent in children than adults, multiple factors, genetic and acquired, may contribute to the development of thrombosis in children (Hoppe and Matsunaga 2002). In children peripheral venous catheters may be a cause of complications. Heparin has been shown to be effective in prolonging the patency of peripheral catheters. The effect of heparin on the duration of these catheters varied across the studies. Because of heterogeneity in clinical outcome recommendations for heparin use in neonates with catheters cannot be made (Shah et al. 2002). LMWH have been applied for prophylaxis and appeared to be safe and efficacious (Dix et al. 2000; Streif et al. 2003; Massicotte et al. 2003). However, the evidence for recommendations for prophylaxis in children is small and there are no general recommendations available.

PROPHYLAXIS IN LONG DISTANCE FLIGHTS

Traveler's thrombosis, also known as "economy class syndrome", has been recognized as a possible complication of long distance flights. In high-risk subjects after long (>10 hours) flights, the incidence of DVT may be between 4% and 6%. High-risk subjects without prophylaxis suffered in 4.82% from DVT, in the aspirin group 3.6% DVT, and none in the LMWH group. DVT was asymptomatic in 60% of subjects. A single dose of LMWH seems to be sufficient for prophylaxis of DVT in

long distance flights (Cesarone et al. 2002). There may be an association of PE and ischemic stroke in passengers with a patent foramen ovale (Lapostolle et al. 2003). However, the etiology of these adverse events needs further clarification before a final recommendation for prophylaxis can be done. High-risk passengers may benefit from a single injection of LMWH (Royal College of Obstetricians and Gynecologists 2001). Epidemiological data, clinical presentation, pathophysiology, and possibilities for prevention were reviewed by Ferrari and Morgan (2004).

PROPHYLAXIS IN ORTHOPEDIC SURGERY

INCIDENCE AND RISK

Thrombosis, affecting approximately 4 million people per year, is the most common cause of mortality in the United States, resulting in more than 2 million deaths per year (Skinner and Schulz 2002). In patients with hip replacement surgery calf vein thrombosis may occur in 40-60% of cases, proximal vein thrombosis in 20% of cases, and fatal pulmonary embolism in 1-2% of cases when prophylaxis is not used (Turpie 1991). Among other risk factors, e.g., inherited thrombophilia, female gender is considered a strong risk factor for venous thrombosis (Svensson et al. 1997). The prevalence of asymptomatic deep vein thrombosis remains high despite 7 to 10 days prophylaxis, as recommended by the American College of Chest Physicians, with a post prophylaxis incidence of nonfatal venous thromboembolism of 2.2% and 0.05% incidence of fatal pulmonary embolism. The post prophylaxis incidence is higher after hip than knee replacement (2.5% versus 1.4%). However, the prevalence of deep vein thrombosis identified by venographic studies was higher after knee than hip replacement (Willan and Crowther 2002; Kearon 2003). In 2000, 53% of hip replacement patients and 47% of knee replacement patients received prophylaxis for longer than 21 days (Anderson et al. 2002). The high risk of DVT has made orthopedic surgery the ideal discipline to test the efficacy and safety of LMWH.

In elective hip replacement LMWH (enoxaparin 40 mg/day) has been successfully tested for prophylaxis of VTE (Planes et al. 1988; Planes et al. 1990; Planes et al. 1991). A comprehensive review on the prevention of deep vein thrombosis in orthopedic surgery has been presented by Eichinger and Kyrle (2004).

TIMING

Fixed-dose LMWH may even be started postoperatively (Turpie 1990; Turpie 1991). Postoperative enoxaparin administration has been successfully used in elective knee arthroplasty (Colwell et al. 1995; Leclerc et al. 1996) Enoxaparin 30 mg twice daily was effective and safe as low dose unfractionated heparin to prevent deep venous thrombosis after hip arthroplasty (Colwell and Spiro 1995). Pre-

operative prophylaxis with LMWH (dalteparin) was more effective than that with warfarin, but there seems to be an increased need for postoperative transfusions and an increase in wound-related bleeding complications (Francis et al. 1997). A modified regimen in close proximity to surgery resulted in substantive risk reductions for all and proximal deep vein thrombosis without increased overt bleeding when initiated postoperatively (Hull et al. 2000).

SIDE EFFECTS AND DOSAGE

LMWH may cause similar or less hemorrhagic events than UH, with a similar rate of deep vein thrombosis (Levine et al. 1991; Warwick et al. 1995). Hemorrhagic side effects may depend on dosage (Spiro et al. 1994). In spinal anesthesia a dose reduction (20mg) has been recommended (Planes et al. 1991).

COST EFFECTIVENESS

In comparison to standard heparin and warfarin, enoxaparin may be cost effective and it can reduce hospital stay (O'Brien et al. 1994; Drummond et al. 1994; Menzin et al. 1994).

PROLONGED ADMINISTRATION

The risk of late-occurring DVT remains high at least until day 35 after surgery (Planes et al. 1996) and several studies demonstrated a beneficial effect when the enoxaparin prophylaxis was prolonged for nine days to one month (Bergqvist et al. 1996; Nilsson et al. 1997; Leclerc et al. 1998). The cost-effectiveness of prolonged enoxaparin prophylaxis after elective hip replacement surgery has been demonstrated (Detournay et al. 1998; Friedman and Dunsworth 2000); this benefit has not been demonstrated for knee replacement (Comp et al. 2001). In several studies LMWHs demonstrated to be safe, effective with major effects on hemostasis (Arnesen et al. 2003; Andersen 1997; Lassen et al. 1998; Dahl et al. 1997; Hull et al. 2000; Hull et al. 2000). It may be interesting to further study the lipolytic effect of LMWH (dalteparin) under these conditions (Myrmel et al. 1992).

COMPARISON WITH OTHER LMWH OR DIRECT THROMBIN INHIBITORS

In recent years enoxaparin prophylaxis in hip and knee replacement surgery has been compared to a synthetic pentasaccharide (Fondaparinux), direct thrombin inhibitor (ximelagatran), and tinzaparin (Planes 2000; Turpie et al. 2001; Heit et al. 2001). Tinzaparin and ximelagatran were found to be equally effective than enoxaparin in these studies; however, other investigators could not repeat the effect of ximelagatran (Eriksson et al. 2003). Fondaparinux was equal or more effective in preventing deep vein thrombosis in several studies in hip or knee replacement surgery (Bauer et al. 2001; Turpie

2001; Lassen et al. 2002; Turpie et al. 2002). In a metaanalysis a superior effect of fondaparinux has been demonstrated in comparison to enoxaparin (Turpie et al. 2002; Turpie et al. 2002).

A direct comparison of three LMWH (certoparin, dalteparin, enoxaparin) showed all three were equally efficacious in the prophylaxis of DVT (Janni et al. 2001). Direct thrombin inhibitors (Ximelagatran and its subcutaneous form melagatran) showed similar results compared to dalteparin in the prophylaxis of DVT (Eriksson et al. 2002; Eriksson et al. 2002). In comparison to enoxaparin, dalteparin as first-line prophylaxis led to substantial cost savings (Krotenberg et al. 2001). Other LMWHs (ardeparin, clivarin, certoparin, nadroparin, tinzaparin, bemiparin, reviparin) have been studied in knee and hip arthroplasty for prophylaxis of DVT, mostly in comparison to enoxaparin (Levine et al. 1996; Heit et al. 1997; Planes 1993; Hamulyak et al. 1995; Planes et al. 1999; Adolf et al. 1999; Blanchard et al. 1999; Kakkar et al. 2000; Heit et al. 2000; Samama et al. 2002; Navarro-Quilis et al. 2003; Wang et al. 2004; Planes et al. 1998; Wirth et al. 2001). Some of the compounds were announced as new second generation LMWH. As inherent differences between LMWHs prevent the extrapolation of clinical outcomes from one trial to another further studies must be awaited before a final recommendation should be given (Deitelzweig et al. 2003).

AMBULATORY SURGERY

In patients undergoing ambulatory arthroscopic knee surgery perioperative and postoperative prophylaxis with a LMWH (dalteparin) was effective and safe (Michot et al. 2002).

CONTROVERSIES

There is an ongoing discussion on several factors, which may have an effect on outcome of thromboprophylaxis.

Timing of initiation of prophylaxis with LMWH remains different in Europe and North America and it is not yet decided what would be the optimal time, although there is some evidence that administration 6 hours postoperatively may be protective without the risk of bleeding (Kher 2001; Dahl and Bergqvist 2002; Strebel et al. 2002; Hull et al. 2001; Hull et al. 1999; Raskob and Hirsh 2003).

The duration of prophylaxis has been studied in multiple randomized trials with success in hip arthroplasty, but not in knee arthroplasty. Adverse effects and cost-effectiveness remain an unsolved issue for some authors whereas others strongly advise the prolonged administration (Whang and Lieberman 2002; Friedman 2003; Hull et al. 2001).

A wide range of model estimates and assumptions identify LMWH (enoxaparin) compared to warfarin or no prophylaxis as the prophylaxis modality of choice for preventing venous thromboembolism and subsequent clinical complications following total knee replacement surgery (Nerurkar et al. 2002).

However, most trials evaluating heparins had methodological defects. UH and LMWH protect against lower limb DVT. There is, however, insufficient evidence to confirm either protection against pulmonary embolism or an overall benefit, or to distinguish between various applications of heparin (Handoll et al. 2002; Anderson et al. 1993). No statistically difference was noted between four prophylactic regimes (aspirin, warfarin, LMWH and pneumatic compression) due to the very small incidence of symptomatic PE (Westrich et al. 2000). For proximal DVT rates, LMWH was significantly better than warfarin – but not for total DVT (Brookenthal et al. 2001). One year earlier it has been stated that the best prophylactic agent in terms of both efficacy and safety was warfarin (Freedman et al. 2000). Another meta-analysis came to the conclusion that LMWH is significantly superior to both UH and warfarin (Palmer et al. 1997). This has led other authors to the conclusion that the absolute reduction in symptomatic venous thromboembolism attributed to extended prophylaxis in some studies and meta-analyses seem to have been overestimated (O'Donnell et al. 2003). It is unclear how much the radiologists experience and frequency of reporting on venograms may have influenced the outcome of these studies (Kalodiki et al. 1998). Furthermore the effect of the administration of LMWH may be influenced by weight and renal function. Weight-based dosing is recommended for some LMWH but not for all (Barrett et al. 2001). The decision to use warfarin or LMWH has then been considered to be a finely tuned trade-off, which is health care system dependent. It is accepted that the most significant parameters that influence the comparative cost-effectiveness are the cost of the drug, the cost of international normalized ratio monitoring and the costs associated with major bleeding (Hull et al. 1997). The prophylaxis with LMWH may also affect the decision which type of anesthesia will be performed. Reports of local bleeding after spinal or epidural analgesia/analgesia make anesthetists more reluctant to combine regional anesthesia with LMWH prophylaxis (Gallus 1999). 48% of orthopedic surgeons had to discontinue LMWH prophylaxis due to bleeding complications. 88% had witnessed excessive bruising around the wound and 53% had experienced increased wound bleeding or hematomas (McNally et al. 1997). A definition on surgical bleeding, which allows practical measurement procedures and quantification, is lacking. Clinical studies on vascular endpoints and standard scientific procedures for health economic analyses have been demanded (Dahl and Bergqvist 2002).

In most studies unfractionated heparin was monitored inappropriately which may be responsible for the reduced efficacy of UH (Raschke et al. 2003).

In summary, LMWHs have chemical, physical, and clinical similarities. They have greater bioavailability, longer half-lives, more predictable pharmacological response, possible improved safety, and similar or greater efficacy compared with UH. However, the evaluation of clinical trials does not

allow the determination of therapeutic equivalence due to different diagnostic methods, drug administration times, dose equivalencies, and outcome measurements (McCart and Kayser 2002). The scoring of the quality of clinical trials for meta-analysis is problematic and it has been recommended to assess the methodological aspects individually (Juni et al. 1999).

Despite clear evidence of effectiveness, deep vein thrombosis prophylaxis is underused. Law firms as evidenced by Internet advertisement have recognized this. Patients are informed on the prevention of venous thromboembolism or economy class syndrome. "If you or a family member has been injured, contact a personal injury attorney today. Just fill out Injury.Board.com's online questionnaire and have a personal injury lawyer review your potential personal injury claim – free of charge." (Injuryboard.com 2004). The medico legal implications of antithrombotic prophylaxis and treatment are well recognized (McIntyre 2001).

REFERENCES

- Adolf J, Fritsche HM, Haas S, Hennig FF, Horbach T, Kastl S, Koppenhagen K, Michaelis HC, Rhamanzadeh R, Summa W, Wagner W, Weber U, Wolf H. Comparison of 3,000 IU aXa of the low molecular weight heparin certoparin with 5,000 IU aXa in prevention of deep vein thrombosis after total hip replacement. German Thrombosis Study Group. *Int Angiol.* 1999 Jun;18(2):122-6
- Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D'Angelo A, Beltrametti C, Damiani M, Andrioli GC, Pugliese R, Iorio A, Brambilla G. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. *N Engl J Med.* 1998 Jul 9;339(2):80-5
- Amarigiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis. *Cochrane Database Syst Rev.* 2000;(3):CD001484
- American College of Obstetricians and Gynecologists. ACOG Committee Opinion: safety of Lovenox in pregnancy. *Obstet Gynecol.* 2002 Oct;100(4):845-6
- Andersen BS. Postoperative activation of the haemostatic system-influence of prolonged thromboprophylaxis in patients undergoing total hip arthroplasty. *Haemostasis.* 1997 Sep-Oct;27(5):219-27
- Anderson DR, O'Brien BJ, Levine MN, Roberts R, Wells PS, Hirsh J. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. *Ann Intern Med.* 1993 Dec 1;119(11):1105-12
- (Anonymus). Deep venous thrombosis and thromboembolism in patients with cervical spinal cord injuries. *Neurosurgery.* 2002 Mar;50(3 Suppl):S73-80
- Arnesen H, Dahl OE, Aspelin T, Seljefflot I, Kierulf P, Lyberg T. Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. *J Thromb Haemost.* 2003 May;1(5):971-5
- Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH. Deep vein thrombosis and its prevention in critically ill adults. *Arch Intern Med.* 2001 May 28;161(10):1268-79
- Barrett JS, Gibiansky E, Hull RD, Planes A, Pentikis H, Hainer JW, Hua TA, Gastonguay M. Population phar-

- macodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. *Int J Clin Pharmacol Ther.* 2001 Oct;39(10):431-46
- Barsotti J, Gruel Y, Rosset P, Favard L, Dabo B, Andreu J, Delahousse B, Leroy J. Comparative double-blind study of two dosage regimens of low-molecular weight heparin in elderly patients with a fracture of the neck of the femur. *J Orthop Trauma.* 1990;4(4):371-5
- Batchelor WB, Mahaffey KW, Berger PB, Deutsch E, Meier S, Hasselblad V, Fry ET, Teirstein PS, Ross AM, Binanay CA, Zidar JP; ATLAST Trial Investigators. A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial. *J Am Coll Cardiol.* 2001 Nov 15;38(6):1608-13
- Bath PM, Lindenstrom E, Boysen G, De Deyn P, Friis P, Leys D, Marttila R, Olsson J, O'Neill D, Orgogozo J, Ringelstein B, van der Sande J, Turpie AG. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. *Lancet.* 2001 Sep 1;358(9283):702-10
- Bates SM. Treatment and prophylaxis of venous thromboembolism during pregnancy. *Thromb Res.* 2002 Nov 1;108(2-3):97-106
- Bauer KA, Eriksson BI, Lassen MR, Turpie AG; Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. *N Engl J Med.* 2001 Nov 1;345(18):1305-10
- Baykal C, Al A, Demirtas E, Ayhan A. Comparison of enoxaparin and standard heparin in gynaecologic oncologic surgery: a randomised prospective double-blind clinical study. *Eur J Gynaecol Oncol.* 2001; 22(2):127-30
- Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. *Lancet.* 2000 Apr 8;355(9211):1205-10
- Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. *Thromb Haemost.* 1996 Oct;76(4):529-34
- Bergqvist D, Matzsch T, Burmark US, Frisell J, Guilbaud O, Hallbook T, Horn A, Lindhagen A, Ljungner H, Ljungstrom KG, et al. Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. *Br J Surg.* 1988 Sep;75(9):888-91
- Bergqvist D, Burmark US, Frisell J, Guilbaud O, Hallbook T, Horn A, Lindhagen A, Ljungner H, Ljungstrom KG, Matzsch T, et al. Thromboprophylactic effect of low molecular weight heparin started in the evening before elective general abdominal surgery: a comparison with low-dose heparin. *Semin Thromb Hemost.* 1990 Oct;16 Suppl:19-24
- Bergqvist D, Burmark US, Frisell J, Guilbaud O, Hallbook T, Horn A, Lindhagen A, Ljungner H, Ljungstrom KG, Matzsch T, et al. Thromboprophylactic effect of low molecular weight heparin started in the evening before elective general abdominal surgery: a comparison with low-dose heparin. *Semin Thromb Hemost.* 1990 Oct;16 Suppl:19-24
- Bergqvist D, Lowe GD, Berstad A, Haas S, Hirsh J, Lassen MR, Samama M, Verhaeghe R. Prevention of venous thromboembolism after surgery: a review of enoxaparin. *Br J Surg.* 1992 Jun;79(6):495-8
- Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallbook T, Hedberg M, Horn A, Kelty E, Kvitting P, Lindhagen A, et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patients. *Br J Surg.* 1995 Apr;82(4):496-501
- Bergqvist D, Flordal PA, Friberg B, Frisell J, Hedberg M, Ljungstrom KG, Matzsch T, Torngren S. Thromboprophylaxis with a low molecular weight heparin (tinzaparin) in emergency abdominal surgery. A double-blind multicenter trial. *Vasa.* 1996;25(2):156-60
- Bergqvist D, Lindgren B, Matzsch T. Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin. *Br J Surg.* 1996 Nov;83(11):1548-52
- Bergqvist D. Prolonged prophylaxis against postoperative venous thromboembolism. *Haemostasis.* 1996 Oct;26 Suppl 4:379-87.
- Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlundh U, Nicolas S, Nilsson P, Nylander G. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. *N Engl J Med.* 1996 Sep 5;335(10):696-700
- Bergqvist D. Venous thromboembolism in cancer patients: expanding horizons. *Semin Thromb Hemost.* 2002 Aug;28 Suppl 3:19-23
- Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F; ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. *N Engl J Med.* 2002 Mar 28;346(13):975-80
- Bhatt DL, Lee BI, Casterella PJ, Pulsipher M, Rogers M, Cohen M, Corrigan VE, Ryan TJ Jr, Breall JA, Moses JW, Eaton GM, Sklar MA, Lincoff AM; Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. Safety of concomitant therapy with eptifibatid and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. *J Am Coll Cardiol.* 2003 Jan 1;41(1):20-5
- Bick RL, Haas S. Thromboprophylaxis and thrombosis in medical, surgical, trauma, and obstetric/gynecologic patients. *Hematol Oncol Clin North Am.* 2003 Feb; 17(1):217-58
- Bick RL, Kaplan BL. Thromboprophylaxis in surgical patients. *Eur J Med Res* 2004;9:104-111
- Bijsterveld NR, Moons AH, Meijers JC, Tijssen JG, Buller HR, Levi M, Peters RJ. Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin. *J Am Coll Cardiol.* 2002 Mar 6;39(5):811-7
- Blanchard J, Meuwly JY, Leyvraz PF, Miron MJ, Bounameaux H, Hoffmeyer P, Didier D, Schneider PA. Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. *J Bone Joint Surg Br.* 1999 Jul;81(4):654-9
- Blomback M, Bremme K, Hellgren M, Lindberg H. A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. *Blood Coagul Fibrinolysis.* 1998 Jun;9(4):343-50
- Boncinelli S, Marsili M, Lorenzi P, Fabbri LP, Pittino S, Filoni M, Bressan F, Sarti E, Cinotti S, Morfini M. Haemostatic molecular markers in patients undergoing radical retropubic prostatectomy for prostate cancer and submitted to prophylaxis with unfractionated or low molecular weight heparin. *Minerva Anesthesiol.* 2001 Oct;67(10):693-703

- Borstad E, Urdal K, Handeland G, Abildgaard U. Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery. *Acta Obstet Gynecol Scand.* 1988;67(2):99-103
- Borstad E, Urdal K, Handeland G, Abildgaard U. Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery. II: Reduced dose of low molecular weight heparin. *Acta Obstet Gynecol Scand.* 1992 Aug;71(6):471-5
- Bounameaux H, Huber O, Khabiri E, Schneider PA, Didier D, Rohner A. Unexpectedly high rate of phlebographic deep venous thrombosis following elective general abdominal surgery among patients given prophylaxis with low-molecular-weight heparin. *Arch Surg.* 1993 Mar;128(3):326-8
- Boneu B. Low molecular weight heparins: are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis? *Thromb Res.* 2000 Oct 15;100(2):V113-20
- Bradbury AW, Chan YC, Darzi A, Stansby G. Thromboembolism prophylaxis during laparoscopic cholecystectomy. *Br J Surg.* 1997 Jul;84(7):962-4
- Breddin HK. Prophylaxis and treatment of deep-vein thrombosis. *Semin Thromb Hemost.* 2000;26 Suppl 1:47-52
- Brenner B, Kupferminc MJ. Inherited thrombophilia and poor pregnancy outcome. *Best Pract Res Clin Obstet Gynaecol.* 2003 Jun;17(3):427-39
- Bridges GG, Lee MD, Jenkins JK, Stephens MA, Croce MA, Fabian TC. Expedited discharge in trauma patients requiring anticoagulation for deep venous thrombosis prophylaxis: the LEAP Program. *J Trauma.* 2003 Feb;54(2):232-5
- Brookenthal KR, Freedman KB, Lotke PA, Fitzgerald RH, Lonner JH. A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. *J Arthroplasty.* 2001 Apr;16(3):293-300
- Burrows RF, Gan ET, Gallus AS, Wallace EM, Burrows EA. A randomised double-blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thrombotic events after caesarean section: a pilot study. *BJOG.* 2001 Aug;108(8):835-9
- Busch M, Masuhr F. Thromboprophylaxis and antithrombotic therapy in patients with ischemic stroke and cerebral venous and sinus thrombosis. *Eur J Med Res* 2004;9(4) (in print)
- Casele HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. *Am J Obstet Gynecol.* 1999 Nov;181(5 Pt 1):1113-7
- Cesarone MR, Belcaro G, Nicolaidis AN, Incandela L, De S, Geroulakos G, Lennox A, Myers KA, Moia M, Ippolito E, Winford M. Venous thrombosis from air travel: the LONFLIT3 study-prevention with aspirin vs low-molecular-weight heparin (LMWH) in high-risk subjects: a randomized trial. *Angiology.* 2002 Jan-Feb;53(1):1-6
- Chiou-Tan FY, Garza H, Chan KT, Parsons KC, Donovan WH, Robertson CS, Holmes SA, Graves DE, Rintala DH. Comparison of dalteparin and enoxaparin for deep venous thrombosis prophylaxis in patients with spinal cord injury. *Am J Phys Med Rehabil.* 2003 Sep;82(9):678-85
- Chojnowski K, Trelinski J, Wawrzyniak E, Robak T. The influence of low molecular weight heparin on the intravascular activation of the coagulation system in patients with acute leukemia during induction chemotherapy-report of a prospective randomized study. *Leuk Lymphoma.* 2002 May;43(5):1021-8
- Choussat R, Montalescot G, Collet JP, Vicaute E, Ankri A, Gallois V, Drobinski G, Sotirov I, Thomas D. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. *J Am Coll Cardiol.* 2002 Dec 4;40(11):1943-50
- Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. *Ann Surg.* 1988 Aug;208(2):227-40
- Cohen AT. Discoveries in thrombosis care for medical patients. *Semin Thromb Hemost.* 2002 Aug;28 Suppl 3:13-7
- Colwell CW Jr, Spiro TE, Trowbridge AA, Stephens JW, Gardiner GA Jr, Riiter MA. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. *Enoxaparin Clinical Trial Group. Clin Orthop.* 1995 Dec;(321):19-27
- Colwell CW Jr, Spiro TE. Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty. *Clin Orthop.* 1995 Oct;(319):215-22
- Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner GA Jr, Landon GC, Jove M; Enoxaparin Clinical Trial Group. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. *Enoxaparin Clinical Trial Group. J Bone Joint Surg Am.* 2001 Mar;83-A(3):336-45
- Cupitt JM. Prophylaxis against thromboembolism in patients with traumatic brain injury: a survey of UK practice. *Anaesthesia.* 2001 Aug;56(8):780-85
- Dahl OE, Andreassen G, Aspelin T, Muller C, Mathiesen P, Nyhus S, Abdelnoor M, Solhaug JH, Arnesen H. Prolonged thromboprophylaxis following hip replacement surgery-results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin) *Thromb Haemost.* 1997 Jan;77(1):26-31
- Dahl OE, Bergqvist D. Current controversies in deep vein thrombosis prophylaxis after orthopaedic surgery. *Curr Opin Pulm Med.* 2002 Sep;8(5):394-7
- Davidson BL. Risk assessment and prophylaxis of venous thromboembolism in acutely and/or critically ill patients. *Haemostasis.* 2000;30 Suppl 2:77-81
- Deitelzweig SB, Vanscoy GJ, Niccolai CS, Rihn TL. Venous thromboembolism prevention with LMWHs in medical and orthopedic surgery patients. *Ann Pharmacother.* 2003 Mar;37(3):402-11
- de Lissoyov G, Subedi P. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective. *Am J Manag Care.* 2002 Dec;8(12):1082-8
- de Pont AC, Oudemans-van Straaten HM, Roozendaal KJ, Zandstra DF. Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study. *Crit Care Med.* 2000 Feb;28(2):421-5
- Detournay B, Planes A, Vochelle N, Fagnani F. Cost effectiveness of a low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement. *Pharmacoeconomics.* 1998 Jan;13(1 Pt 1):81-9
- Deutsch E. The emerging role of low-molecular-weight heparin and antiplatelet therapies in the cardiac catheterization laboratory. *Am Heart J.* 1999 Dec;138(6 Pt 2):S577-85
- Dickinson LD, Miller LD, Patel CP, Gupta SK. Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. *Neurosurgery.* 1998 Nov;43(5):1074-81
- Dix D, Andrew M, Marzinotto V, Charpentier K, Bridge S, Monagle P, deVeber G, Leaker M, Chan AK, Massicotte MP. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. *J Pediatr.* 2000 Apr;136(4):439-45

- Dorffler-Melly J, Buller H, Koopman M, Prins M. Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. *Cochrane Database Syst Rev.* 2003;4:CD000536
- Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. *Arch Intern Med.* 2000 Dec 11;25;160(22):3431-6
- Douketis JD. Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians. *Thromb Res.* 2002 Oct 1;108(1):3-13
- Drummond M, Aristides M, Davies L, Forbes C. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. *Br J Surg.* 1994 Dec;81(12):1742-6
- Edmondson RA, Cohen AT, Das SK, Wagner MB, Kakkar VV. Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. *Lancet.* 1994 Oct 1;344(8927):914-8
- Eichinger S, Kyrle PA. Prevention of deep vein thrombosis in orthopedic surgery. *Eur J Med Res* 2004;9:112-118
- Ellison J, Walker ID, Greer IA. Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. *BJOG.* 2000 Sep;107(9):1116-21
- Ellison J, Thomson AJ, Conkie JA, McCall F, Walker D, Greer A. Thromboprophylaxis following caesarean section—a comparison of the antithrombotic properties of three low molecular weight heparins—dalteparin, enoxaparin and tinzaparin. *Thromb Haemost.* 2001 Dec;86(6):1374-8
- Enoxacan Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. *ENOXACAN Study Group. Br J Surg.* 1997 Aug;84(8):1099-103
- Eriksson BI, Bauer KA, Lassen MR, Turpie AG; Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. *N Engl J Med.* 2001 Nov 1;345(18):1298-304.
- Eriksson BI, Arfwidsson AC, Frison L, Eriksson UG, Bylock A, Kalebo P, Fager G, Gustafsson D. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MELagatran for THRombin inhibition in Orthopaedic surgery. *Thromb Haemost.* 2002 Feb;87(2):231-7
- Eriksson BI, Bergqvist D, Kalebo P, Dahl OE, Lindbratt S, Bylock A, Frison L, Eriksson UG, Welin L, Gustafsson D; Melagatran for Thrombin inhibition in Orthopaedic surgery. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. *Lancet.* 2002 Nov 9;360(9344):1441-7
- Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosenthal N, Eskilson C, Nylander I, Frison L, Ogren M; METHRO III Study Group. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. *Thromb Haemost.* 2003 Feb;89(2):288-96
- Eskander MB, Limb D, Stone MH, Furlong AJ, Shardlow D, Stead D, Culleton G. Sequential mechanical and pharmacological thromboprophylaxis in the surgery of hip fractures. A pilot study. *Int Orthop.* 1997;21(4):259-61
- Etchells E, McLeod RS, Geerts W, Barton P, Detsky AS. Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery. *Arch Intern Med.* 1999 Jun 14;159(11):1221-8
- European Fraxiparin Study Group. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. The European Fraxiparin Study (EFS) Group. *Br J Surg.* 1988 Nov;75(11):1058-63
- Fanikos J, Tsilimingras K, Kucher N, Rosen AB, Hieblinger MD, Goldhaber SZ. Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation. *Am J Cardiol.* 2004 Jan 15;93(2):247-50
- Farkas JC, Chapuis C, Combe S, Silsiguen M, Marzelle J, Laurian C, Cormier JM. A randomised controlled trial of a low-molecular-weight heparin (Enoxaparin) to prevent deep-vein thrombosis in patients undergoing vascular surgery. *Eur J Vasc Surg.* 1993 Sep;7(5):554-60
- Ferrari E, Morgan G. Travel as risk factor for venous thromboembolic disease. *Eur J Med Res* 2004;9:146-149
- Ferreira I, Dos L, Tornos P, Nicolau I, Permyner-Miralda G, Soler-Soler J. Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol. *Heart.* 2003 May;89(5):527-30
- Filtensborg Tvedskov T, Rasmussen MS, Wille-Jørgensen P. Survey of the use of thromboprophylaxis in laparoscopic surgery in Denmark. *Br J Surg.* 2001 Oct;88(10):1413-6
- Flordal PA, Bergqvist D, Burmark US, Ljungstrom KG, Torngren S. Risk factors for major thromboembolism and bleeding tendency after elective general surgical operations. The Fragmin Multicentre Study Group. *Eur J Surg.* 1996 Oct;162(10):783-9
- Fraisse F, Holzapfel L, Couland JM, Simonneau G, Bedock B, Feissel M, Herbecq P, Pordes R, Poussel JF, Roux L. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. *Am J Respir Crit Care Med.* 2000 Apr;161(4 Pt 1):1109-14
- Francis CW, Pellegrini VD Jr, Totterman S, Boyd AD Jr, Marder VJ, Liebert KM, Stulberg BN, Ayers DC, Rosenberg A, Kessler C, Johanson NA. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. *J Bone Joint Surg Am.* 1997 Sep;79(9):1365-72
- Freedman KB, Brookenthal KR, Fitzgerald RH Jr, Williams S, Lonner JH. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. *J Bone Joint Surg Am.* 2000 Jul;82-A(7):929-38
- Fricker JP, Vergnes Y, Schach R, Heitz A, Eber M, Grunebaum L, Wiesel ML, Kher A, Barbier P, Cazenave JP. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. *Eur J Clin Invest.* 1988 Dec;18(6):561-7
- Friederich PW, Sanson BJ, Simioni P, Zanardi S, Huisman MV, Kindt I, Prandoni P, Buller HR, Girolami A, Prins MH. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient

- women: implications for prophylaxis. *Ann Intern Med.* 1996 Dec 15;125(12):955-60
- Friedman RJ, Dunsworth GA. Cost analyses of extended prophylaxis with enoxaparin after hip arthroplasty. *Clin Orthop.* 2000 Jan;(370):171-82
- Friedman RJ. Extended thromboprophylaxis after hip or knee replacement. *Orthopedics.* 2003 Feb;26(2 Suppl):s225-30
- Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Pieper K, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL 3rd, Michelson AD. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab. *Am Heart J.* 2001 Nov;142(5):790-8
- Gallus AS. Applying risk assessment models in orthopaedic surgery: overview of our clinical experience. *Blood Coagul Fibrinolysis.* 1999 Aug;10 Suppl 2:S53-61
- Gardlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. *Lancet.* 1996 May 18;347(9012):1357-61
- Gates S, Brocklehurst P, Davis LJ. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. *Cochrane Database Syst Rev.* 2002;(2):CD001689
- Gathof BS, Picker SM, Rojo J. Epidemiology, etiology, and diagnosis of venous thrombosis. *Eur J Med Res* 2004;9:95-103
- Gebhardt GS, Hall DR. Inherited and acquired thrombophilias and poor pregnancy outcome: should we be treating with heparin? *Curr Opin Obstet Gynecol.* 2003 Dec; 15(6): 501-6
- Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, Hamilton PA. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. *N Engl J Med.* 1996 Sep 5;335(10):701-7
- Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA, Wheeler HB. Prevention of venous thromboembolism. *Chest* 2001;119:132S-175S
- Gibson JL, Ekevall K, Walker I, Greer IA. Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. *Br J Obstet Gynaecol.* 1998 Jul;105(7):795-7
- Ginsberg JS, Chan WS, Bates SM, Kaatz S. Anticoagulation of pregnant women with mechanical heart valves. *Arch Intern Med.* 2003 Mar 24;163(6):694-8
- Ginzburg E, Cohn SM, Lopez J, Jackowski J, Brown M, Hameed SM; Miami Deep Vein Thrombosis Study Group. Randomized clinical trial of intermittent pneumatic compression and low molecular weight heparin in trauma. *Br J Surg.* 2003 Nov;90(11):1338-44
- Glick A, Kornowski R, Michowich Y, Koifman B, Roth A, Laniado S, Keren G. Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. *Am J Cardiol.* 1996 Jun 1;77(14):1145-8
- Goldhaber SZ, Dunn K, Gerhard-Herman M, Park JK, Black PM. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. *Chest.* 2002 Dec;122(6):1933-7
- Gondret R, Dominici L, Angelard B, Dubos S, al-Rawi S, Huet Y, Clergue F, Saint-Guily JL. Safety of preoperative enoxaparin in head and neck cancer surgery. *Head Neck.* 1995 Jan-Feb;17(1):1-6
- Grassman ED, Leya F, Fareed J, Lewis BE, Bacher P, Loeb HS, Moran JF. A randomized trial of the low-molecular-weight heparin certoparin to prevent restenosis following coronary angioplasty. *J Invasive Cardiol.* 2001 Nov;13(11):723-8
- Green D, Lee MY, Lim AC, Chmiel JS, Vetter M, Pang T, Chen D, Fenton L, Yarkony GM, Meyer PR Jr. Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin. *Ann Intern Med.* 1990 Oct 15;113(8):571-4
- Green D, Chen D, Chmiel JS, Olsen NK, Berkowitz M, Novick A, Alleva J, Steinberg D, Nussbaum S, Tolotta M, et al. Prevention of thromboembolism in spinal cord injury: role of low molecular weight heparin. *Arch Phys Med Rehabil.* 1994 Mar;75(3):290-2
- Greenfield LJ, Proctor MC, Rodriguez JL, Luchette FA, Cipolle MD, Cho J. Posttrauma thromboembolism prophylaxis. *J Trauma.* 1997 Jan;42(1):100-3
- Greer IA. Exploring the role of low-molecular-weight heparins in pregnancy. *Semin Thromb Hemost.* 2002 Aug;28 Suppl 3:25-31
- Greer IA. Inherited thrombophilia and venous thromboembolism. *Best Pract Res Clin Obstet Gynaecol.* 2003 Jun;17(3):413-25
- Greer IA. Prevention of venous thromboembolism in pregnancy. *Eur J Med Res* 2004;9:135-145
- Haas S, Flosbach CW. Prevention of postoperative thromboembolism with Enoxaparin in general surgery: a German multicenter trial. *Semin Thromb Hemost.* 1993;19 Suppl 1:164-73
- Haentjens P. Thromboembolic prophylaxis in orthopaedic trauma patients: a comparison between a fixed dose and an individually adjusted dose of a low molecular weight heparin (nadroparin calcium) *Injury.* 1996 Jul;27(6):385-90
- Hague WM, North RA, Gallus AS, Walters BN, Orlikowski C, Burrows RF, Cincotta RB, Dekker GA, Higgins JR, Lowe SA, Morris JM, Peek MJ; Working Group on behalf of the Obstetric Medicine Group of Australasia. Anticoagulation in pregnancy and the puerperium. *Med J Aust.* 2001 Sep 3;175(5):258-63
- Hak DJ. Prevention of venous thromboembolism in trauma and long bone fractures. *Curr Opin Pulm Med.* 2001 Sep;7(5):338-43
- Hamulyak K, Lensing AW, van der Meer J, Smid WM, van Ooy A, Hoek JA. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? *Fraxiparine Oral Anticoagulant Study Group. Thromb Haemost.* 1995 Dec;74(6):1428-31
- Handoll HH, Farrar MJ, McBirnie J, Tytherleigh-Strong G, Milne AA, Gillespie WJ. Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures. *Cochrane Database Syst Rev.* 2002;(4):CD000305
- Harenberg J, Kallenbach B, Martin U, Dempfle CE, Zimmermann R, Kubler W, Heene DL. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. *Thromb Res.* 1990 Aug 1;59(3):639-50
- Harenberg J, Weuster B, Pfitzer M, Dempfle CE, Stehle G, Kubler W, Schlierf G. Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin. *Semin Thromb Hemost.* 1993;19 Suppl 1:116-21
- Harenberg J, Roebuck P, Heene DL. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group. *Haemostasis.* 1996 May-Jun;26(3):127-39
- Harris S, Chen D, Green D. Enoxaparin for thromboembolism prophylaxis in spinal injury: preliminary re-

- port on experience with 105 patients. *Am J Phys Med Rehabil.* 1996 Sep-Oct;75(5):326-7
- Hartl P, Brucke P, Dienstl E, Vinazzar H. Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin. *Thromb Res.* 1990 Feb 15;57(4):577-84
- Heilmann L, Schneider DM, von Tempelhoff GF. Antithrombotic therapy in high-risk pregnancy. *Hematol Oncol Clin North Am.* 2000 Oct;14(5):1133-50, ix
- Heit JA, Berkowitz SD, Bona R, Cabanas V, Corson JD, Elliott CG, Lyons R. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. *Ardeparin Arthroplasty Study Group. Thromb Haemost.* 1997 Jan;77(1):32-8
- Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med.* 2000 Jun 6;132(11):853-61
- Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J, Peters G; AstraZeneca Arthroplasty Study Group. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. *Arch Intern Med.* 2001 Oct 8;161(18):2215-21
- Hillbom M, Erila T, Sotaniemi K, Tatlisumak T, Sarna S, Kaste M. Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study. *Acta Neurol Scand.* 2002 Aug;106(2):84-92
- Ho YH, Seow-Choen F, Leong A, Eu KW, Nyam D, Teoh MK. Randomized, controlled trial of low molecular weight heparin vs. no deep vein thrombosis prophylaxis for major colon and rectal surgery in Asian patients. *Dis Colon Rectum.* 1999 Feb;42(2):196-202
- Hoppe C, Matsunaga A. Pediatric thrombosis. *Pediatr Clin North Am.* 2002 Dec;49(6):1257-83
- Howard PA. Low molecular weight heparins in special populations. *J Infus Nurs.* 2003 Sep-Oct;26(5):304-10
- Huang JN, Shimamura A. Low-molecular-weight heparins. *Hematol Oncol Clin North Am.* 1998 Dec;12(6):1251-81, vi-vii
- Hull RD, Raskob GE, Pineo GF, Feldstein W, Rosenbloom D, Gafni A, Green D, Feinglass J, Trowbridge AA, Elliott CG. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. *Arch Intern Med.* 1997 Feb 10;157(3):298-303
- Hull RD, Brant RF, Pineo GF, Stein PD, Raskob GE, Valentine KA. Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement. *Arch Intern Med.* 1999 Jan 25;159(2):137-41
- Hull RD. New insights into extended prophylaxis after orthopaedic surgery - the North American Fragmin Trial experience. *Haemostasis.* 2000;30 Suppl 2:95-100; discussion 82-3
- Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, Holmqvist A, Mant M, Dear R, Baylis B, Mah A, Brant R. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. *Arch Intern Med.* 2000 Jul 4;160(14):2199-207
- Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, Holmqvist A, Mant M, Dear R, Baylis B, Mah A, Brant R. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. *Arch Intern Med.* 2000 Jul 24;160(14):2208-15
- Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE, Ghali WA, Butcher MS, Brant RF, Bergqvist D, Hamulyak K, Francis CW, Marder VJ, Raskob GE. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. *Arch Intern Med.* 2001 Sep 10;161(16):1952-60
- Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE, Butcher M, Brant RF, Ghali WA, Bergqvist D, Raskob GE. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. *Ann Intern Med.* 2001 Nov 20;135(10):858-69
- Injuryboard.com <http://www.injuryboard.com>
- Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. *Arch Intern Med.* 2000 Aug 14-28;160(15):2327-32
- Jacobsen AF, Qvigstad E, Sandset PM. Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. *BJOG.* 2003 Feb;110(2):139-44
- Jafri SM. Periprocedural thromboprophylaxis in patients receiving chronic anticoagulation therapy. *Am Heart J.* 2004 Jan;147(1):3-15
- Janssen MJ, Deegens JK, Kapinga TH, Beukhof JR, Huijgens PC, van Loenen AC, van der Meulen J. Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients. *Kidney Int.* 1996 Mar;49(3):806-13
- Janni W, Bergauer F, Rjosk D, Lohscheidt K, Hagen FW. [Prospective randomized study comparing the effectiveness and tolerance of various low-molecular-weight heparins in high risk patients] *Zentralbl Chir.* 2001 Jan;126(1):32-8
- Jorgensen PS, Knudsen JB, Broeng L, Josephsen L, Bjerregaard P, Hagen K, Jorgensen PK, Torholm C. The thromboprophylactic effect of a low-molecular-weight heparin (Fragmin) in hip fracture surgery. A placebo-controlled study. *Clin Orthop.* 1992 May;(278):95-100
- Jorgensen LN, Wille-Jorgensen P, Hauch O. Prophylaxis of postoperative thromboembolism with low molecular weight heparins. *Br J Surg.* 1993 Jun;80(6):689-704
- Jorgensen PS, Warming T, Hansen K, Paltved C, Vibeke Berg H, Jensen R, Kirchhoff-Jensen R, Kjaer L, Kerbouche N, Leth-Espensen P, Narvestad E, Rasmussen SW, Sloth C, Torholm C, Wille-Jorgensen P. Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a venographic controlled study. *Thromb Res.* 2002 Mar 15;105(6):477-80
- Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. *JAMA.* 1999 Sep 15;282(11):1054-60
- Kakkar VV. Efficacy and safety of Clivarin and other LMWHs in general surgery: a meta-analysis. *Blood Coagul Fibrinolysis.* 1993 Dec;4 Suppl 1:S23-7
- Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK, Maher KT, Sanderson RM, Ward VP, Kakkar S. Low molecular weight versus standard heparin for prevention of venous thromboembolism

- after major abdominal surgery. The Thromboprophylaxis Collaborative Group. *Lancet*. 1993 Jan 30; 341(8840):259-65
- Kakkar VV, Boeckl O, Boneu B, Bordenave L, Brehm OA, Brucke P, Coccheri S, Cohen AT, Galland F, Haas S, Jarrige J, Koppenhagen K, LeQuerrec A, Paraguet E, Prandoni P, Roder JD, Roos M, Ruschemeyer C, Siewert JR, Vinazzer H, Wenzel E. Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial. *World J Surg*. 1997 Jan;21(1):2-8
- Kakkar VV, De Lorenzo F. Prevention of venous thromboembolism in general surgery. *Baillieres Clin Haematol*. 1998 Sep;11(3):605-19
- Kakkar VV, Howes J, Sharma V, Kadziola Z. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group. *Thromb Haemost*. 2000 Apr;83(4):523-9
- Kakkar AK. An expanding role for antithrombotic therapy in cancer patients. *Cancer Treat Rev*. 2003 Jun;29 Suppl 2:23-6
- Kalodiki E, Nicolaidis AN, Al-Kutoubi A, Cunningham DA, Mandalia S. How "gold" is the standard? Interobservers' variation on venograms. *Int Angiol*. 1998 Jun;17(2):83-8
- Kerciakes DJ, Kleiman NS, Fry E, Mwawasi G, Lengerich R, Maresh K, Burkert ML, Aquilina JW, DeLoof M, Broderick TM, Shimshak TM. Dalteparin in combination with abciximab during percutaneous coronary intervention. *Am Heart J*. 2001 Mar;141(3):348-52
- Kew J, Lee YL, Davey IC, Ho SY, Fung KC, Metreweli C. Deep vein thrombosis in elderly Hong Kong Chinese with hip fractures detected with compression ultrasound and Doppler imaging: incidence and effect of low molecular weight heparin. *Arch Orthop Trauma Surg*. 1999;119(3-4):156-8
- Kher A. Critical appraisal of current antithrombotic trials in patients undergoing total hip replacement. *Expert Opin Investig Drugs*. 2001 Dec;10(12):2175-83
- Khushal A, Quinlan D, Alikhan R, Gardner J, Bailey C, Cohen A. Thromboembolic disease in surgery for malignancy-rationale for prolonged thromboprophylaxis. *Semin Thromb Hemost*. 2002 Dec;28(6):569-76
- Kincaid EH, Monroe ML, Saliba DL, Kon ND, Byerly WG, Reichert MG. Effects of preoperative enoxaparin versus unfractionated heparin on bleeding indices in patients undergoing coronary artery bypass grafting. *Ann Thorac Surg*. 2003 Jul;76(1):124-8
- Kleber FX, Witt C, Vogel C, Koppenhagen K, Schomaker U, Flosbach CW; THE PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. *Am Heart J*. 2003 Apr;145(4):614-21
- Kleinschmidt K, Charles R. Pharmacology of low molecular weight heparins. *Emerg Med Clin North Am*. 2001 Nov;19(4):1025-49
- Klerk CP, Smorenburg SM, Buller HR. Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review. *Arch Intern Med*. 2003 Sep 8;163(16):1913-21
- Knudson MM, Morabito D, Paiement GD, Shackelford S. Use of low molecular weight heparin in preventing thromboembolism in trauma patients. *J Trauma*. 1996 Sep;41(3):446-59
- Koch A, Bouges S, Ziegler S, Dinkel H, Daures JP, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: update of previous meta-analyses. *Br J Surg*. 1997 Jun;84(6):750-9
- Koch A, Ziegler S, Breitschwerdt H, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis: meta-analysis based on original patient data. *Thromb Res*. 2001 May 15;102(4):295-309
- Kock HJ, Schmit-Neuerburg KP, Hanke J, Rudofsky G, Hirche H. Thromboprophylaxis with low-molecular-weight heparin in outpatients with plaster-cast immobilisation of the leg. *Lancet*. 1995 Aug 19;346(8973):459-61
- Kujath P, Spannagel U, Habscheid W. Incidence and prophylaxis of deep venous thrombosis in outpatients with injury of the lower limb. *Haemostasis*. 1993 Mar;23 Suppl 1:20-6
- Krottenberg R, Adler U, Pomeranz B, Miller JD, Russell MW. Dalteparin vs. enoxaparin as prophylaxis for deep-vein thrombosis after total hip or knee arthroplasty: a retrospective analysis. *Am J Phys Med Rehabil*. 2001 Dec;80(12):889-95
- Kujath P, Eckmann C, Misselwitz F. Low-molecular-weight heparin in arterial reconstructive surgery: a double-blind, randomized dose-finding trial. *Clin Appl Thromb Hemost*. 2002 Oct;8(4):337-45
- Lamy A, Wang X, Kent R, Smith KM, Gafni A. Economic evaluation of the MEDENOX trial: a Canadian perspective. *Medical Patients with Enoxaparin*. *Can Respir J*. 2002 May-Jun;9(3):169-77
- Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejo Bro HP, Andersen G, Petersen AO, Siem P, Horlyck E, Jensen BV, Thomsen PB, Hansen BR, Erin-Madsen J, Moller JC, Rotwitt L, Christensen F, Nielsen JB, Jorgensen PS, Paaske B, Torholm C, Hvidt P, Jensen NK, Nielsen AB, Appelquist E, Tjalve E, et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty-the Danish Prolonged Prophylaxis (DaPP) Study. *Thromb Res*. 1998 Mar 15;89(6):281-7
- Lassen MR, Borris LC, Nakov RL. Use of the low-molecular-weight heparin rivaroxan to prevent deep-vein thrombosis after leg injury requiring immobilization. *N Engl J Med*. 2002 Sep 5;347(10):726-30
- Lassen MR, Bauer KA, Eriksson BI, Turpie AG; European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. *Lancet*. 2002 May 18;359(9319):1715-20
- Laurent P, Dussarat GV, Bonal J, Jeco C, Talard P, Bouchiat C, Cellarier G. Low molecular weight heparins: a guide to their optimum use in pregnancy. *Drugs*. 2002;62(3):463-77
- Lausen I, Jensen R, Wille-Jorgensen P, Jorgensen LN, Rasmussen MS, Lyng KM, Andersen M, Raaschou HO. Colour Doppler flow imaging ultrasonography versus venography as screening method for asymptomatic post-operative deep venous thrombosis. *Eur J Radiol*. 1995 Sep;20(3):200-4
- Lausen I, Jensen R, Jorgensen LN, Rasmussen MS, Lyng KM, Andersen M, Raaschou HO, Wille-Jorgensen P. Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. *Eur J Surg*. 1998 Sep;164(9):657-63
- Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. *Haemostasis*. 1996;26 Suppl 2:49-56

- Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, L'Esperance B, Demers C, Kassis J, Cruickshank M, Whitman L, Delorme F. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. *Ann Intern Med.* 1996 Apr 1;124(7):619-26
- Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. *Arch Intern Med.* 1998 Apr 27;158(8):873-8
- Lee AY. The role of low-molecular-weight heparins in the prevention and treatment of venous thromboembolism in cancer patients. *Curr Opin Pulm Med.* 2003 Sep;9(5):351-5
- Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. *N Engl J Med.* 2003 Jul 10;349(2):146-53
- Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. *BMJ.* 1992 Oct 17;305(6859):913-20
- Leizorovicz A, Bara L, Samama MM, Haugh MC. Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. *Haemostasis.* 1993 Mar;23 Suppl 1:89-98
- Levine MN, Hirsh J, Gent M, Turpie AG, Leclerc J, Powers PJ, Jay RM, Neemeh J. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. *Ann Intern Med.* 1991 Apr 1;114(7):545-51
- Levine MN, Gent M, Hirsh J, Weitz J, Turpie AG, Powers P, Neemeh J, Willan A, Skingley P. Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery. *Arch Intern Med.* 1996 Apr 22;156(8):851-6
- Levine MN. Can we optimise treatment of thrombosis? *Cancer Treat Rev.* 2003 Jun;29 Suppl 2:19-22
- Leyh RT, Fischer S, Ruhparwar A, Haverich A. Anticoagulant therapy in pregnant women with mechanical heart valves. *Arch Gynecol Obstet.* 2003 Apr;268(1):1-4. Epub 2003 Jan 14.
- Lord RV, Ling JJ, Hugh TB, Coleman MJ, Doust BD, Nivison-Smith I. Incidence of deep vein thrombosis after laparoscopic vs minilaparotomy cholecystectomy. *Arch Surg.* 1998 Sep;133(9):967-73
- Lyrer P, Engelter S. Antithrombotic drugs for carotid artery dissection. *Cochrane Database Syst Rev.* 2003;(3):CD000255
- Macdonald RL, Amidei C, Baron J, Weir B, Brown F, Erickson RK, Hekmatpanah J, Frim D. Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy. *Surg Neurol.* 2003 May;59(5):363-72; discussion 372-4
- Mahesh B, Evans S, Bryan AJ. Failure of low molecular-weight heparin in the prevention of prosthetic mitral valve thrombosis during pregnancy: case report and a review of options for anticoagulation. *J Heart Valve Dis.* 2002 Sep;11(5):745-50
- Makatsaria AD, Bitsadze VO, Dolgushina NV. Use of the low-molecular-weight heparin nadroparin during pregnancy. A review. *Curr Med Res Opin.* 2003;19(1):4-12
- Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B, Chan AK, Andrew M; PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. *Thromb Res.* 2003 Jan 25;109(2-3):101-8
- Maxwell GL, Synan I, Dodge R, Carroll B, Clarke-Pearson DL. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. *Obstet Gynecol.* 2001 Dec;98(6):989-95
- McCart GM, Kayser SR. Therapeutic equivalency of low-molecular-weight heparins. *Ann Pharmacother.* 2002 Jun;36(6):1042-57
- McIntyre K. Medicolegal implications of the consensus conference. *Chest* 2001;119:337S-343S
- McLeod RS, Geerts WH, Sniderman KW, Greenwood C, Gregoire RC, Taylor BM, Silverman RE, Atkinson KG, Burnstein M, Marshall JC, Burul CJ, Anderson DR, Ross T, Wilson SR, Barton P; Canadian Colorectal Surgery DVT Prophylaxis Trial investigators. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial. *Ann Surg.* 2001 Mar;233(3):438-44
- McNally MA, Cooke EA, Harding ML, Mollan RA. Attitudes to, and utilization of, low molecular weight heparins in joint replacement surgery. *J R Coll Surg Edinb.* 1997 Dec;42(6):407-9
- Medalion B, Frenkel G, Patachenko P, Hauptman E, Sasson L, Schachner A. Preoperative use of enoxaparin is not a risk factor for postoperative bleeding after coronary artery bypass surgery. *J Thorac Cardiovasc Surg.* 2003 Dec;126(6):1875-9
- Meneveau N, Schiele F, Grollier G, Farah B, Lablanche JM, Khalife K, Machecourt J, Danchin N, Wolf JE, Simpson M, Hak JB, Bassand JP. Local delivery of nadroparin for the prevention of neointimal hyperplasia following stent implantation: results of the IMPRESS trial. A multicentre, randomized, clinical, angiographic and intravascular ultrasound study. *Eur Heart J.* 2000 Nov;21(21):1767-75
- Menzin J, Richner R, Huse D, Colditz GA, Oster G. Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation. *Ann Pharmacother.* 1994 Feb;28(2):271-5
- Merli GJ, Crabbe S, Paluzzi RG, Fritz D. Etiology, incidence, and prevention of deep vein thrombosis in acute spinal cord injury. *Arch Phys Med Rehabil.* 1993 Nov;74(11):1199-205
- Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. *Arch Intern Med.* 2002 Aug 12-26;162(15):1729-35
- Michot M, Conen D, Holtz D, Erni D, Zumstein MD, Ruffin GB, Renner N. Prevention of deep-vein thrombosis in ambulatory arthroscopic knee surgery: A randomized trial of prophylaxis with low-molecular weight heparin. *Arthroscopy.* 2002 Mar;18(3):257-63

- Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2002 May 7;136(9):680-90
- Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. *Br J Surg.* 2001 Jul;88(7):913-30
- Mismetti P, Mille D, Laporte S, Charlet V, Buchmuller-Cordier A, Jacquin JP, Fournel P, Dutrey-Dupagne C, Decousus H; CIP Study Group. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. *Haematologica.* 2003 Jan;88(1):67-73
- Myrmet T, Larsen TS, Reikeras O. Lipolytic effect of low-molecular-weight-heparin (Fragmin) and heparin/dihydroergotamine in thromboprophylactic doses during total hip replacement. *Scand J Clin Lab Invest.* 1992 Nov;52(7):741-5
- Moliterno DJ, Hermiller JB, Kerciakes DJ, Yow E, Applegate RJ, Braden GA, Dippel EJ, Furman MI, Grines CL, Kleiman NS, Levine GN, Mann T 3rd, Nair RN, Stine RA, Yacubov SJ, Tchong JE; ELECT Investigators. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. *J Am Coll Cardiol.* 2003 Sep 17;42(6):1132-9
- Monreal M, Lafoz E, Navarro A, Granero X, Caja V, Caceres E, Salvador R, Ruiz J. A prospective double-blind trial of a low molecular weight heparin once daily compared with conventional low-dose heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients with hip fracture. *J Trauma.* 1989 Jun;29(6):873-5
- Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. *Thromb Haemost.* 1994 Jan;71(1):7-11
- Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A. Upper extremity deep venous thrombosis in cancer patients with venous access devices: prophylaxis with a low molecular weight heparin (Fragmin). *Thromb Haemost.* 1996 Feb;75(2):251-3
- Montalescot G, Polle V, Collet JP, Leprince P, Bellanger A, Gandjbakhch I, Thomas D. Low molecular weight heparin after mechanical heart valve replacement. *Circulation.* 2000 Mar 14;101(10):1083-6
- Mousa SA. The low molecular weight heparin, tinzaparin, in thrombosis and beyond. *Cardiovasc Drug Rev.* 2002 Fall;20(3):199-216
- Muntz JE. Deep vein thrombosis and pulmonary embolism in the perioperative patient. *Am J Manag Care.* 2000 Nov;6(20 Suppl):S1045-52
- Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? *Arch Intern Med.* 2002 Dec 9-23;162(22):2605-9
- Navarro-Quilis A, Castellet E, Rocha E, Paz-Jimenez J, Planes A; Bemiparin Study Group in Knee Arthroplasty. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial. *J Thromb Haemost.* 2003 Mar;1(3):425-32
- Nelson-Piercy C, Letsky EA, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. *Am J Obstet Gynecol.* 1997 May;176(5):1062-8
- Nerurkar J, Wade WE, Martin BC. Cost/death averted with venous thromboembolism prophylaxis in patients undergoing total knee replacement or knee arthroplasty. *Pharmacotherapy.* 2002 Aug;22(8):990-1000
- Nilsson PE, Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlund U, Nicolas S, Nylander G. The postdischarge prophylactic management of the orthopedic patient with low-molecular-weight heparin: enoxaparin. *Orthopedics.* 1997 Feb;20 Suppl:22-5
- Norwood SH, McAuley CE, Berne JD, Vallina VL, Kerns DB, Graham TW, McLarty JW. A potentially expanded role for enoxaparin in preventing venous thromboembolism in high risk blunt trauma patients. *J Am Coll Surg.* 2001 Feb;192(2):161-7
- Norwood SH, McAuley CE, Berne JD, Vallina VL, Kerns DB, Graham TW, Short K, McLarty JW. Prospective evaluation of the safety of enoxaparin prophylaxis for venous thromboembolism in patients with intracranial hemorrhagic injuries. *Arch Surg.* 2002 Jun;137(6):696-701
- Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP, Briet E. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. *Lancet.* 1992 Jul 18;340(8812):152-6
- Nurmohamed MT, Verhaeghe R, Haas S, Iriarte JA, Vogel G, van Rij AM, Prentice CR, ten Cate JW. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. *Am J Surg.* 1995 Jun;169(6):567-71
- Nurmohamed MT, van Riel AM, Henkens CM, Koopman MM, Que GT, d'Azemar P, Buller HR, ten Cate JW, Hoek JA, van der Meer J, van der Heul C, Turpie AG, Haley S, Sicurella A, Gent M. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. *Thromb Haemost.* 1996 Feb;75(2):233-8
- Oates-Whitehead R, D'Angelo A, Mol B. Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. *Cochrane Database Syst Rev.* 2003;4:CD003679
- O'Brien BJ, Anderson DR, Goeree R. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. *CMAJ.* 1994 Apr 1;150(7):1083-90
- Ockelford PA, Patterson J, Johns AS. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). *Thromb Haemost.* 1989 Dec;62(4):1046-9
- O'Donnell M, Linkins LA, Kearon C, Julian J, Hirsh J. Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review. *Arch Intern Med.* 2003 Jun 9;163(11):1362-6
- Owings JT, Blaisdell FW. Low-dose heparin thromboembolism prophylaxis. *Arch Surg.* 1996 Oct;131(10):1069-73
- Palmer AJ, Schramm W, Kirchhof B, Bergemann R. Low molecular weight heparin and unfractionated heparin for prevention of thromboembolism in general surgery: a meta-analysis of randomised clinical trials. *Haemostasis.* 1997 Mar-Apr;27(2):65-74
- Palmer AJ, Koppenhagen K, Kirchhof B, Weber U, Bergemann R. Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for

- thromboembolism prophylaxis in orthopaedic surgery: a meta-analysis of randomised clinical trials. *Haemostasis*. 1997 Mar-Apr;27(2):75-84
- Pan M, Suarez de Lezo J, Velasco F, Romero M, Medina A, Segura J, Hernandez E, Pavlovic D, Melian F, Gallardo A, Zayas R, Ruiz M, Torres A. Reduction of thrombotic and hemorrhagic complications after stent implantation. *Am Heart J*. 1996 Dec;132(6):1119-26
- Petralia G, Kakkar AK. Antithrombotic therapy with low molecular weight heparin in cancer patients. *Eur J Med Res* 2004;9:119-124
- Pettila V, Kaaja R, Leinonen P, Ekblad U, Kataja M, Ikkala E. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. *Thromb Res*. 1999 Nov 15;96(4):275-82
- Pettila V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. *Thromb Haemost*. 2002 Feb;87(2):182-6
- Planes A, Vochelle N, Mazas F, Mansat C, Zucman J, Landais A, Pascariello JC, Weill D, Butel J. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. *Thromb Haemost*. 1988 Dec 22;60(3):407-10
- Planes A, Vochelle N, Fagola M, Bellaud M, Feret J, Salzard C, Planes M. Once-daily dosing of enoxaparin (a low molecular weight heparin) in prevention of deep vein thrombosis after total hip replacement. *Acta Chir Scand Suppl*. 1990;556:108-15
- Planes A, Vochelle N, Fagola M, Bellaud M, Feret J, Salzard C, Planes M. Efficacy and safety of a perioperative enoxaparin regimen in total hip replacement under various anesthetics. *Am J Surg*. 1991 Apr;161(4):525-31
- Planes A, Vochelle N, Fagola M, Feret J, Bellaud M. Prevention of deep vein thrombosis after total hip replacement. The effect of low-molecular-weight heparin with spinal and general anaesthesia. *J Bone Joint Surg Br*. 1991 May;73(3):418-22
- Planes A. Comparison of antithrombotic efficacy and haemorrhagic side-effects of Clivarin versus enoxaparin in patients undergoing total hip replacement surgery. *Blood Coagul Fibrinolysis*. 1993 Dec;4 Suppl 1:S33-5; discussion S37-8
- Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. *Lancet*. 1996 Jul 27;348(9022):224-8
- Planes A, Vochelle N, Fagola M, Bellaud M. Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. *Reviparin Study Group. Blood Coagul Fibrinolysis*. 1998 Sep;9(6):499-505.
- Planes A, Samama MM, Lensing AW, Buller HR, Barre J, Vochelle N, Beau B. Prevention of deep vein thrombosis after hip replacement-comparison between two low-molecular heparins, tinzaparin and enoxaparin. *Thromb Haemost*. 1999 Jan;81(1):22-5
- Planes A. An equivalence study of two low-molecular-weight heparins in the prevention and treatment of deep-vein thrombosis after total hip replacement. *Semin Thromb Hemost*. 2000;26 Suppl 1:57-60
- Priglinger U, Delle Karth G, Geppert A, Joukhadar C, Graf S, Berger R, Hulsmann M, Spitzauer S, Pabinger I, Heinz G. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill? *Crit Care Med*. 2003 May;31(5):1405-9
- Prins MH, Gelsema R, Sing AK, van Heerde LR, den Otlander GJ. Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. *Haemostasis*. 1989;19(5):245-50
- Raschke R, Hirsh J, Guidry JR. Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. *Ann Intern Med*. 2003 May 6;138(9):720-3
- Raskob GE, Hirsh J. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. *Chest*. 2003 Dec;124(6 Suppl):379S-385S
- Rasmussen MS. Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged thromboprophylaxis. *Cancer Treat Rev*. 2002 Jun;28(3):141-4
- Reeves JH, Cumming AR, Gallagher L, O'Brien JL, Santamaria JD. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. *Crit Care Med*. 1999 Oct;27(10):2224-8
- Rostoker G, Durand-Zaleski I, Petit-Phar M, Ben Maadi A, Jazaerli N, Radier C, Rahmouni A, Mathieu D, Vasile N, Rosso J, et al. Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin. *Nephron*. 1995;69(1):20-8
- Rowan JA, McCowan LM, Raudkivi PJ, North RA. Enoxaparin treatment in women with mechanical heart valves during pregnancy. *Am J Obstet Gynecol*. 2001 Sep;185(3):633-7
- Royal College of Obstetricians and Gynecologists. Advice on preventing deep vein thrombosis for pregnant women travelling by air. Scientific advisory committee opinion paper 1. October 2001
- Ryan KE, Lane DA, Flynn A, Shepperd J, Ireland HA, Curtis JR. Dose finding study of a low molecular weight heparin, Innohep, in haemodialysis. *Thromb Haemost*. 1991 Sep 2;66(3):277-82.
- Sagedal S, Hartmann A. Low molecular weight heparins as thromboprophylaxis in patients undergoing hemodialysis/hemofiltration or continuous renal replacement therapies. *Eur J Med Res* 2004;9:125-130
- Samama M, Bernard P, Bonnardot JP, Combe-Tamzali S, Lanson Y, Tissot E. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. *Br J Surg*. 1988 Feb;75(2):128-31
- Samama CM, Gigou F, Ill P. Low-molecular-weight heparin vs. unfractionated heparin in femorodistal reconstructive surgery: a multicenter open randomized study. *Enoxart Study Group. Ann Vasc Surg*. 1995;9 Suppl:S45-53
- Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. *Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med*. 1999 Sep 9;341(11):793-800
- Samama CM, Vray M, Barre J, Fiessinger JN, Rosencher N, Lecompte T, Potron G, Basile J, Hull R, Desmichels D; SACRE Study Investigators. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. *Arch Intern Med*. 2002 Oct 28;162(19):2191-6
- Sandset PM, Dahl T, Stiris M, Rostad B, Scheel B, Abildgaard U. A double-blind and randomized placebo-

- bo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. *Semin Thromb Hemost.* 1990 Oct;16 Suppl:25-33
- Sarasin FP, Bounameaux H. Cost-effectiveness of prophylactic anticoagulation prolonged after hospital discharge following general surgery. *Arch Surg.* 1996 Jul;131(7):694-7
- Schenk P, Rosenkranz AR, Wolf G, Horl WH, Traindl O. Recombinant tissue plasminogen activator is a useful alternative to heparin in priming quinton permcath. *Am J Kidney Dis.* 2000 Jan;35(1):130-6
- Schweizer J, Muller A, Forkmann L, Hellner G, Kirch W. Potential use of a low-molecular-weight heparin to prevent restenosis in patients with extensive wall damage following peripheral angioplasty. *Angiology.* 2001 Oct;52(10):659-69
- Sephton V, Farquharson RG, Topping J, Quenby SM, Cowan C, Back DJ, Toh CH. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. *Obstet Gynecol.* 2003 Jun;101(6):1307-11
- Shah PS, Ng E, Sinha AK. Heparin for prolonging peripheral intravenous catheter use in neonates. *Cochrane Database Syst Rev.* 2002; (4): CD002774
- Shorr AF, Ramage AS. Enoxaparin for thromboprophylaxis after major trauma: potential cost implications. *Crit Care Med.* 2001 Sep;29(9):1659-65
- Siegerstetter V, Krause T, Rossle M, Haag K, Ochs A, Hauenstein KH, Moser HE. Transjugular intrahepatic portosystemic shunt (TIPS). Thrombogenicity in stents and its effect on shunt patency. *Acta Radiol.* 1997 Jul;38(4 Pt 1):558-64
- Siironen J, Juvela S, Varis J, Porras M, Poussa K, Ilveskero S, Hernesniemi J, Lassila R. No effect of enoxaparin on outcome of aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled clinical trial. *J Neurosurg.* 2003 Dec;99(6):953-9
- Skinner HB, Schulz MM. Clinical implications of thromboprophylaxis in the management of total hip and knee arthroplasty. *Am J Orthop.* 2002;31(9 Suppl):20-30
- Sonaglia F, Agnelli G, Baroni M, Severi P, Quintavalla R, D'Angelo SV. Pre-operative plasma levels of soluble fibrin polymers correlate with the development of deep vein thrombosis after elective neurosurgery. *Blood Coagul Fibrinolysis.* 1999 Dec;10(8): 459-63
- Spandorfer JM, Lynch S, Weitz HH, Fertel S, Merli GJ. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. *Am J Cardiol.* 1999 Aug 15;84(4):478-80, A10
- Spannagel U, Kujath P. Low molecular weight heparin for the prevention of thromboembolism in outpatients immobilized by plaster cast. *Semin Thromb Hemost.* 1993;19 Suppl 1:131-41
- Spinal Cord Injury Thromboprophylaxis Investigators. Prevention of venous thromboembolism in the rehabilitation phase after spinal cord injury: prophylaxis with low-dose heparin or enoxaparin. *J Trauma.* 2003 Jun;54(6):1111-5
- Spinal Cord Injury Thromboprophylaxis Investigators. Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin. *J Trauma.* 2003 Jun;54(6):1116-24; discussion 1125-6
- Spiro TE, Johnson GJ, Christie MJ, Lyons RM, MacFarlane DE, Blasler RB, Tremaine MD. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Enoxaparin Clinical Trial Group. *Ann Intern Med.* 1994 Jul 15;121(2):81-9
- Stables RH, Sigwart U. Post-stent management with a pneumatic groin compression device and self injected low molecular weight heparin. *Heart.* 1996 Jun;75(6): 588-90
- Storti S, Crucitti P, Cina G. Risk factors and prevention of venous thromboembolism. *Rays.* 1996 Jul-Sep;21(3): 439-60
- Stratton MA, Anderson FA, Bussey HI, Caprini J, Comcroft A, Haines ST, Hawkins DW, O'Connell MB, Smith RC, Stringer KA. Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients. *Arch Intern Med.* 2000 Feb 14;160(3):334-40
- Strebel N, Prins M, Agnelli G, Buller HR. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? *Arch Intern Med.* 2002 Jul 8;162(13):1451-6
- Streif W, Goebel G, Chan AK, Massicotte MP. Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients. *Arch Dis Child Fetal Neonatal Ed.* 2003 Sep;88(5):F365-70
- Thaler HW, Roller RE, Greiner N, Sim E, Korninger C. Thromboprophylaxis with 60 mg enoxaparin is safe in hip trauma surgery. *J Trauma.* 2001 Sep;51(3):518-21
- The TIFDED Study Group. Thromboprophylaxis in hip fracture surgery: a pilot study comparing danaparoid, enoxaparin and dalteparin. *Haemostasis.* 1999 Nov-Dec;29(6):310-7
- Tincani A, Branch W, Levy RA, Piette JC, Carp H, Rai RS, Khamashta M, Shoenfeld Y. Treatment of pregnant patients with antiphospholipid syndrome. *Lupus.* 2003;12(7):524-9
- Triolo G, Ferrante A, Ciccio F, Accardo-Palumbo A, Perino A, Castelli A, Giarratano A, Licata G. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. *Arthritis Rheum.* 2003 Mar; 48(3):728-31
- Tsimoyiannis EC, Floras G, Antoniou N, Papanikolaou N, Siakas P, Tassis A. Low-molecular-weight heparins and Daflon for prevention of postoperative thromboembolism. *World J Surg.* 1996 Oct;20(8):968-71
- Turpie AG. Enoxaparin prophylaxis in elective hip surgery. *Acta Chir Scand Suppl.* 1990;556:103-7
- Turpie AG. Efficacy of a postoperative regimen of enoxaparin in deep vein thrombosis prophylaxis. *Am J Surg.* 1991 Apr;161(4):532-6
- Turpie AG. Successors to heparin: new antithrombotic agents. *Am Heart J.* 1997 Nov;134(5 Pt 2):S71-7
- Turpie AG. Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. *Am J Cardiol.* 2000 Dec 28;86(12B):48M-52M
- Turpie AG, Gallus AS, Hoek JA; Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. *N Engl J Med.* 2001 Mar 1;344(9):619-25
- Turpie AG. Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice. *Am Heart J.* 2001 Aug;142(2 Suppl):S9-15
- Turpie AG, Bauer KA, Eriksson BI, Lassen MR; PENTATHALON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. *Lancet.* 2002 May 18;359(9319): 1721-6
- Turpie AG, Eriksson BI, Lassen MR, Bauer KA. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. *J South Orthop Assoc.* 2002 Winter;11(4):182-8

- Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. *Arch Intern Med.* 2002 Sep 9;162(16):1833-40
- Vaitkus PT, Leizorovicz A, Goldhaber SZ; PREVENT Investigator Group. Rationale and design of a clinical trial of a low-molecular-weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). *Vasc Med.* 2002;7(4):269-73
- Vaitkus PT. Thromboprophylaxis in immobilized medical patients. *Eur J Med Res* 2004;9:131-134
- van Gorp EC, Brandjes DP, ten Cate JW. Rational antithrombotic therapy and prophylaxis in elderly, immobile patients. *Drugs Aging.* 1998 Aug;13(2):145-57
- Velmahos GC, Oh Y, McCombs J, Oder D. An evidence-based cost-effectiveness model on methods of prevention of posttraumatic venous thromboembolism. *J Trauma.* 2000 Dec;49(6):1059-64
- von Tempelhoff GF, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L. Blood coagulation and thrombosis in patients with ovarian malignancy. *Thromb Haemost.* 1997 Mar;77(3):456-61.
- von Tempelhoff GF, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ, Heilmann L. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial. *Int J Oncol.* 2000 Apr;16(4):815-24
- Voth D, Schwarz M, Hahn K, Dei-Anang K, al Butmeh S, Wolf H. Prevention of deep vein thrombosis in neurosurgical patients: a prospective double-blind comparison of two prophylactic regimen. *Neurosurg Rev.* 1992;15(4):289-94
- Vukovich TC, Gabriel A, Schaeffer B, Veitl M, Matula C, Spiss CK. Hemostasis activation in patients undergoing brain tumor surgery. *J Neurosurg.* 1997 Oct;87(4):508-11
- Wade WE, Chisholm MA. Deep venous thrombosis prophylaxis in trauma: cost analysis. *Blood Coagul Fibrinolysis.* 2000 Jan;11(1):101-6
- Walker MC, Ferguson SE, Allen VM. Heparin for pregnant women with acquired or inherited thrombophilias. *Cochrane Database Syst Rev.* 2003; (2): CD003580
- Walsh DC, Kakkar AK. Thromboembolism in brain tumors. *Curr Opin Pulm Med.* 2001 Sep;7(5):326-31
- Wang CJ, Wang JW, Weng LH, Hsu CC, Huang CC, Yu PC. Prevention of deep-vein thrombosis after total knee arthroplasty in Asian patients. Comparison of low-molecular-weight heparin and indomethacin. *J Bone Joint Surg Am.* 2004 Jan;86-A(1):136-40
- Warwick D, Bannister GC, Glew D, Mitchelmore A, Thornton M, Peters TJ, Brookes S. Perioperative low-molecular-weight heparin. Is it effective and safe. *J Bone Joint Surg Br.* 1995 Sep;77(5):715-9
- Watson HR, Belcher G, Horrocks M. Adjuvant medical therapy in peripheral bypass surgery. *Br J Surg.* 1999 Aug;86(8):981-91
- Westrich GH, Haas SB, Mosca P, Peterson M. Meta-analysis of thromboembolic prophylaxis after total knee arthroplasty. *J Bone Joint Surg Br.* 2000 Aug;82(6):795-800
- Whang PG, Lieberman JR. Extended-duration low-molecular-weight heparin prophylaxis following total joint arthroplasty. *Am J Orthop.* 2002 Sep;31(9 Suppl):31-6
- Wiig JN, Solhaug JH, Bilberg T, Bjerkeset T, Edwin B, Gruner OP, Havig O, Holter O, Knudsen G, Lundblad R, et al. Prophylaxis of venographically diagnosed deep vein thrombosis in gastrointestinal surgery. Multicentre trials 20 mg and 40 mg enoxaparin versus dextran. *Eur J Surg.* 1995 Sep;161(9):663-8
- Wille-Jorgensen P, Lausen I, Nannestad Jorgensen L. Is there a need for long-term thromboprophylaxis following general surgery? *Haemostasis.* 1993 Mar;23 Suppl 1:10-4
- Wille-Jorgensen P, Rasmussen M, Andersen B, Borly L. Heparins and mechanical methods for thromboprophylaxis in colorectal surgery. *Cochrane Database Syst Rev.* 2003;4:CD001217
- Wilson NV, Melissari E, Standfield NJ, Kakkar VV. Intraoperative antithrombotic therapy with low molecular weight heparin in aortic surgery. How should heparin be administered? *Eur J Vasc Surg.* 1991 Oct;5(5):565-9
- Wirth T, Schneider B, Misselwitz F, Lomb M, Tuylu H, Egbring R, Griss P. Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin): Results of a randomized controlled trial. *Arthroscopy.* 2001 Apr;17(4):393-9
- Younis JS, Ohel G, Brenner B, Haddad S, Lanir N, Ben-Ami M. The effect of thromboprophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation. *BJOG.* 2000 Mar;107(3):415-9
- Zidar JP. Rationale for low-molecular weight heparin in coronary stenting. *Am Heart J.* 1997 Nov;134(5 Pt 2):S81-7
- Zidar JP. Low-molecular-weight heparins in coronary stenting (the ENTICES trial). Enoxaparin and TI-Clopidine after Elective Stenting. *Am J Cardiol.* 1998 Sep 10;82(5B):29L-32L

Received: March 10, 2004 / Accepted: March 22, 2004

Address for correspondence:

René Gordon Holzheimer MD PhD
Blombergstr. 5
D-82054 Sauerlach (Munich South)
Tel. +49-8104-887822
Fax +49-8104-887824
e-mail Gresser.holzheimer@t-online.de
www.praxisklinik-sauerlach.de